The ethics of feedback of HIV test results in population-based surveys of HIV infection

Bulletin of the World Health Organization
Volume 91, Number 12, December 2013, 897-972http://www.who.int/bulletin/volumes/91/12/en/index.html

POLICY & PRACTICE
The ethics of feedback of HIV test results in population-based surveys of HIV infection
Dermot Maher
doi: 10.2471/BLT.13.117309
http://www.who.int/bulletin/volumes/91/12/13-117309-ab/en/index.html

Abstract
Population-based disease prevalence surveys raise ethical questions, including whether participants should be routinely told their test results. Ethical guidelines call for informing survey participants of any clinically relevant finding to enable appropriate management. However, in anonymous surveys of human immunodeficiency virus (HIV) infection, participants can “opt out” of being given their test results or are offered the chance to undergo voluntary HIV testing in local counselling and testing services. This is aimed at minimizing survey participation bias.    Those who opt out of being given their HIV test results and who do not seek their results miss the opportunity to receive life-saving antiretroviral therapy.

The justification for HIV surveys without routine feedback of results to participants is based on a public health utility argument: that the benefits of more rigorous survey methods – reduced participation bias – outweigh the benefits to individuals of knowing their HIV status. However, people with HIV infection have a strong immediate interest in knowing their HIV status. In consideration of the ethical value of showing respect for people and thereby alleviating suffering, an argument based on public health utility is not an appropriate justification.

In anonymous HIV surveys as well as other prevalence surveys of treatable conditions in any setting, participation should be on the basis of routine individual feedback of results as an integral part of fully informed participation. Ensuring that surveys are ethically sound may stimulate participation, increase a broader uptake of HIV testing and reduce stigmatization of people who are HIV-positive.

Rapid monitoring in vaccination campaigns during emergencies: the post-earthquake campaign in Haiti

Bulletin of the World Health Organization
Volume 91, Number 12, December 2013, 897-972http://www.who.int/bulletin/volumes/91/12/en/index.html

Rapid monitoring in vaccination campaigns during emergencies: the post-earthquake campaign in Haiti
Jeanette J Rainey, David Sugerman, Muireann Brennan, Jean Ronald Cadet, Jackson Ernsly, François Lacapère, M Carolina Danovaro-Holliday, Jean-Claude Mubalama & Robin Nandy
Problem
The earthquake that struck Haiti in January 2010 caused 1.5 million people to be displaced to temporary camps. The Haitian Ministry of Public Health and Population and global immunization partners developed a plan to deliver vaccines to those residing in these camps. A strategy was needed to determine whether the immunization targets set for the campaign were achieved.

Approach
Following the vaccination campaign, staff from the Ministry of Public Health and Population interviewed convenience samples of households – in specific predetermined locations in each of the camps – regarding receipt of the emergency vaccinations. A camp was targeted for “mop-up vaccination” – i.e. repeat mass vaccination – if more than 25% of the children aged 9 months to 7 years in the sample were found not to have received the emergency vaccinations.

Local setting
Rapid monitoring was implemented in camps located in the Port-au-Prince metropolitan area. Camps that housed more than 5000 people were monitored first.

Relevant changes
By the end of March 2010, 72 (23%) of the 310 vaccinated camps had been monitored. Although 32 (44%) of the monitored camps were targeted for mop-up vaccination, only six of them had received such repeat mass vaccination when checked several weeks after monitoring.

Lessons learnt
Rapid monitoring was only marginally beneficial in achieving immunization targets in the temporary camps in Port-au-Prince. More research is needed to evaluate the utility of conventional rapid monitoring, as well as other strategies, during post-disaster vaccination campaigns that involve mobile populations, particularly when there is little capacity to conduct repeat mass vaccination.
http://www.who.int/bulletin/volumes/91/12/12-117044-ab/en/index.html

Prevention of sexually transmitted infections among girls and young women in relation to their HPV vaccination status

The European Journal of Public Health
Volume 23 Issue 6 December 2013
http://eurpub.oxfordjournals.org/content/current

Prevention of sexually transmitted infections among girls and young women in relation to their HPV vaccination status
Delphine Lutringer-Magnin1,2, Julie Kalecinski3, Claire Cropet1, Giovanna Barone1, Vincent Ronin1, Véronique Régnier3, Yann Leocmach4, Anne-Carole Jacquard4, Philippe Vanhems2,5, Franck Chauvin3 and Christine Lasset1,2

Author Affiliations
1 Département de santé publique, Centre Léon Bérard, Lyon, France
2 Laboratoire de biométrie et biologie évolutive, Université Lyon 1, CNRS UMR 5558, Villeurbanne, France
3 Département de santé publique, Institut de Cancérologie Lucien Neuwirth, CIC-EC 3 Inserm, IFR 143, Saint-Etienne, France
4 Sanofi Pasteur MSD, Lyon, France
5 Département d’Hygiène, Epidémiologie et Prévention, Hospices Civils de Lyon, Lyon, France
Correspondence: Christine Lasset, Université Lyon 1, CNRS UMR 5558 Centre Léon Bérard, 28, rue Laennec, 69373 Lyon cedex 08, France, tel: +33 4 78 78 27 52, fax: +33 4 78 78 27 15,

Abstract
Background: Having been vaccinated against the human papilloma virus (HPV) may affect other behaviours related to sexual health. This study assessed knowledge and behaviour relevant to the prevention of sexually transmitted infections (STIs) among girls/women aged 14–23 years in relation to their HPV vaccination status.

Methods: From November 2008 to February 2009, 328 girls/women from the Rhône-Alpes region were recruited by general practitioners and completed a self-administered questionnaire. Results: In all, 316 of the 328 respondents provided information on their HPV vaccination status: 135 (42.7%) had been vaccinated (51.2% of girls aged 14–16 years, 44% of women aged 17–20 years and 18.9% of 21–23-year-olds). Knowledge about HPV and the Pap smear was poor overall but greater in those who had been vaccinated: vaccinated 14–16-year-olds were significantly more likely to know the aim of the Pap smear than those not vaccinated (72.7% vs. 41.3%, P < 0.001), and vaccinated 21–23-year-olds were more likely to know about the need to continue Pap smear screening, despite vaccination (60.0% vs. 25.6%, P = 0.06). Irrespective of vaccination status, >80% cited condoms as a means of STI prevention and >85% of those who were sexually active used them. No difference was observed between vaccinated and non-vaccinated groups regarding requests for HIV serology, history of abortions or emergency hormonal contraception.

Conclusion: Knowledge about cervical cancer prevention was better among those who had been vaccinated against HPV than among those who had not. Knowledge and behaviour relevant to STI prevention seemed appropriate whatever the respondents’ vaccination status.

COMMENTARY: Routine immunization – an essential but wobbly platform

Global Health: Science and Practice (GHSP)
November 2013 | Volume 1 | Issue 3
http://www.ghspjournal.org/content/current
[“A new no fee, open-access journal, was developed for global health professionals, particularly program implementers, to validate their experiences and program results by peer reviewers and to share them with the greater global health community.”]

COMMENTARIES
Routine immunization: an essential but wobbly platform
Robert Steinglass
Glob Health Sci Pract 2013;1(3):295-301. http://dx.doi.org/10.9745/GHSP-D-13-0012
http://www.ghspjournal.org/content/1/3/295.full

Abstract
Despite their vital role, routine immunization programs are taken for granted. Coverage levels are poor in some countries and have stagnated in others, while addition of new vaccines is an additional stressor. We need to strengthen: (1) policy processes, (2) monitoring and evaluation, (3) human resources, (4) regular delivery and supply systems, (5) local political commitment and ownership, (6) involvement of civil society and communities, and (7) sustainable financing. Rebalancing immunization direction and investment is needed.

Factors limiting immunization coverage in urban Dili, Timor-Leste

Global Health: Science and Practice (GHSP)
November 2013 | Volume 1 | Issue 3
http://www.ghspjournal.org/content/current
[“A new no fee, open-access journal, was developed for global health professionals, particularly program implementers, to validate their experiences and program results by peer reviewers and to share them with the greater global health community.”]

Factors limiting immunization coverage in urban Dili, Timor-Leste
Ruhul Amina, Telma Joana Corte Real De Oliveirab, Mateus Da Cunhab, Tanya Wells Brownc,
a href=”http://www.ghspjournal.org/search?author1=Michael+Favin&sortspec=date&submit=Submit”>Michael Favina, Kelli Cappeliera
Author Affiliations
aMCHIP-Maternal and Child Health Integrated Program, John Snow, Inc., Washington, DC, USA
bThe Ministry of Health, Dili, Timor-Leste
cU.S. Agency for International Development, Dili, Timor-Leste
Correspondence to Ruhul Amin (dr_ruhul@yahoo.com).

Simple access to immunization services does not necessarily translate into uptake of services. In Timor-Leste, key determinants of the success of vaccination efforts are health workers’ attitudes, the manner in which patients are treated, aspects of service organization, adequate supply of vaccines, and caregivers’ basic knowledge about immunization.
http://www.ghspjournal.org/content/1/3/417.abstract

ABSTRACT
Background: Timor-Leste’s immunization coverage is among the poorest in Asia. The 2009/2010 Demographic and Health Survey found that complete vaccination coverage in urban areas, at 47.7%, was lower than in rural areas, at 54.1%. The city of Dili, the capital of Timor-Leste, had even lower coverage (43.4%) than the national urban average.

Objective: To better understand the service- and user-related factors that account for low vaccination coverage in urban Dili, despite high literacy rates and relatively good access to immunization services and communication media.

Methods: A mixed-methods (mainly qualitative) study, conducted in 5 urban sub-districts of Dili, involved in-depth interviews with18 Ministry of Health staff and 6 community leaders, 83 observations of immunization encounters, 37 exit interviews with infants’ caregivers at 11 vaccination sites, and 11 focus group discussions with 70 caregivers of vaccination-eligible children ages 6 to 23 months.

Results: The main reasons for low vaccination rates in urban Dili included caregivers’ knowledge, attitudes, and perceptions as well as barriers at immunization service sites. Other important factors were access to services and information, particularly in the city periphery, health workers’ attitudes and practices, caregivers’ fears of side effects, conflicting priorities, large family size, lack of support from husbands and paternal grandmothers, and seasonal migration.

Conclusion: Good access to health facilities or health services does not necessarily translate into uptake of immunization services. The reasons are complex and multifaceted but in general relate to the health services’ insufficient understanding of and attention to their clients’ needs. Almost all families in Dili would be motivated to have their children immunized if services were convenient, reliable, friendly, and informative.

World Medical Association: Declaration of Helsinki – 7th Revision & Commentary

JAMA   
November 27, 2013, Vol 310, No. 20
http://jama.jamanetwork.com/issue.aspx

Viewpoint | November 27, 2013
The 50th Anniversary of the Declaration of Helsinki- Progress but Many Remaining Challenges
Joseph Millum, PhD1,2; David Wendler, PhD1; Ezekiel J. Emanuel, MD, PhD3,4
[+] Author Affiliations
JAMA. 2013;310(20):2143-2144. doi:10.1001/jama.2013.281632.
Excerpt [Free full text: http://jama.jamanetwork.com/article.aspx?articleid=1760320 ]

Since 1964, through 7 revisions, the World Medical Association’s (WMA’s) Declaration of Helsinki has stood as an important statement regarding the ethical principles guiding medical research with human participants. The declaration is consulted by ethics review committees, funders, researchers, and research participants; has been incorporated into national legislation; and is routinely invoked to ascertain the ethical appropriateness of clinical trials.

There is much to praise about the revision process and the latest revision, which coincides with the declaration’s 50th anniversary. The Working Group extensively consulted stakeholders and justified the proposed revisions. The result is a declaration that is better organized into clear sections, more precise, and likely to be more effective at protecting research participants.

For the first time, the declaration requires compensation and treatment for research-related injuries (paragraph 15), an explicit recognition that research participants should not bear the costs of research gone wrong.1 The revised declaration’s emphasis on the dissemination of research results, including studies with negative results, should increase the value of medical research (paragraphs 23, 35, and 36).

Nevertheless, the proposed declaration contains persistent flaws. While the document purports to be a statement of enduring ethical principles, the nearly continuous process of revision undermines its authority.2 Moreover, the declaration continues to assert that “consistent with the mandate of the WMA,” its primary audience is physicians (paragraph 2).    This is a mistake. Indeed, the document then offers recommendations for other health professionals (paragraph 9), research ethics committees (paragraph 23), sponsors and governments (paragraph 34), and editors and publishers (paragraph 36). It is time for the WMA to recognize that the Declaration of Helsinki should address physicians as well other health professionals and personnel involved in research. A statement of ethical principles does not require a mandate from the people who ought to follow those principles.2

The revised declaration’s treatment of informed consent remains inadequate. It fails to recognize the possibility of waiving consent for some research involving competent adults, even though such research is common and widely endorsed. Similarly, the declaration avoids providing guidance on when it can be appropriate to ask participants to give broad consent for their biological samples to be used in a wide range of future studies, rather than seeking consent for each specific study. This is a pressing issue on which researchers need clear guidance. In addition, the declaration prohibits individuals who cannot consent from participating in research that does not address the condition that caused their incapacity (paragraph 30), even when the research offers participants the potential for important medical benefit and there are no—or few—potential participants who can consent. This approach transforms a protection into a barrier….

Viewpoint | November 27, 2013
The Declaration of Helsinki, 50 Years Later
Paul Ndebele, PhD1
JAMA. 2013;310(20):2145-2146. doi:10.1001/jama.2013.281316.
Excerpt [Free full-text: http://jama.jamanetwork.com/article.aspx?articleid=1760319 ]

Fifty years and 7 revisions later, the 2013 version of the Declaration of Helsinki includes several important changes. By changing the format and including several subsections, the revised declaration enhances and improves clarity regarding specific issues. By having specific issues covered under these subsections, the declaration is now “ bolder” in the way it addresses specific issues. The new formatting will also be welcomed by readers because the subsections improve the readability of the document. By so doing, the Declaration of Helsinki is a better and more important authority at what it is aimed at achieving—providing guidance on conducting medical research involving humans.

The increase in international studies over the past few decades has contributed to serious debate about the ethics of research conducted in various settings. Most of the debate centered on issues related to limited resources and justice: use of placebo and posttrial access to interventions. Through this and previous revisions, the World Medical Association (WMA) has demonstrated that the declaration is a living document that considers current issues in medical research. Important documents such as the declaration are expected to respond to new areas of need or areas that require revision…

Special Communication | November 27, 2013
World Medical Association: Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects
World Medical Association
JAMA. 2013;310(20):2191-2194. doi:10.1001/jama.2013.281053.
Full text of newest  version adopted by the 64th WMA General Assembly, Fortaleza, Brazil, October 2013: http://jama.jamanetwork.com/article.aspx?articleid=1760318

WHO’s 2013 global report on tuberculosis: successes, threats, and opportunities

The Lancet  
Nov 30, 2013  Volume 382  Number 9907  p1757 – 1856  e26 – 32
http://www.thelancet.com/journals/lancet/issue/current

Comment
WHO’s 2013 global report on tuberculosis: successes, threats, and opportunities
Alimuddin Zumla, Andrew George, Virendra Sharma, Nick Herbert, Baroness Masham of Ilton

Preview |
Tuberculosis has been a global public health emergency since 1993.1 In 2006 WHO launched the Stop TB strategy, which was linked to the Millennium Development Goal (MDG) 6 target of reversing the spread of tuberculosis by 2015.2 WHO’s Global Tuberculosis Report 2013,3 published on Oct 23, provides a comprehensive assessment of the current tuberculosis pandemic, and assesses progress in implementing tuberculosis services and control measures at country, regional, and global levels.3 The report details some striking successes towards achieving MDG 6 and related 2015 targets for global tuberculosis control.

The drug and vaccine landscape for neglected diseases (2000—11): a systematic assessment

The Lancet Global Health
Dec 2013  Volume 1  Number 6  e310 – 379
http://www.thelancet.com/journals/langlo/issue/current

Articles
The drug and vaccine landscape for neglected diseases (2000—11): a systematic assessment
Dr Belen Pedrique MD a, Nathalie Strub-Wourgaft MD a, Claudette Some PharmD b, Piero Olliaro MD c d, Patrice Trouiller PharmD e, Nathan Ford PhD f, Bernard Pécoul MD a, Jean-Hervé Bradol MD g
http://www.thelancet.com/journals/langlo/article/PIIS2214-109X%2813%2970078-0/abstract

Summary
Background
In 1975—99, only 1·1% of new therapeutic products had been developed for neglected diseases. Since then, several public and private initiatives have attempted to mitigate this imbalance. We analysed the research and development pipeline of drugs and vaccines for neglected diseases from 2000 to 2011.

Methods
We searched databases of drug regulatory authorities, WHO, and clinical trial registries for entries made between Jan 1, 2000, and Dec 31, 2011. We defined neglected diseases as malaria, tuberculosis, diarrhoeal diseases, neglected tropical diseases (NTDs; WHO definition), and other diseases of poverty according to common definitions.

Findings
Of the 850 new therapeutic products registered in 2000—11, 37 (4%) were indicated for neglected diseases, comprising 25 products with a new indication or formulation and eight vaccines or biological products. Only four new chemical entities were approved for neglected diseases (three for malaria, one for diarrhoeal disease), accounting for 1% of the 336 new chemical entities approved during the study period. Of 148 445 clinical trials registered in Dec 31, 2011, only 2016 (1%) were for neglected diseases.

Interpretation
Our findings show a persistent insufficiency in drug and vaccine development for neglected diseases. Nevertheless, these and other data show a slight improvement during the past 12 years in new therapeutics development and registration. However, for many neglected diseases, new therapeutic products urgently need to be developed and delivered to improve control and potentially achieve elimination.

Funding
None.

Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine

New England Journal of Medicine
November 28, 2013  Vol. 369 No. 22
http://www.nejm.org/toc/nejm/medical-journal

Perspective
The Quest for an HIV-1 Vaccine — Moving Forward
Dan H. Barouch, M.D., Ph.D.
N Engl J Med 2013; 369:2073-2076November 28, 2013DOI: 10.1056/NEJMp131271

Excerpt
Vaccines have historically been the most effective biomedical interventions for controlling global infectious diseases. The development of a safe and effective vaccine against human immunodeficiency virus type 1 (HIV-1) is therefore a critical research priority. Although other HIV-1 prevention efforts based on behavioral risk reduction, male circumcision, topical microbicides, preexposure prophylaxis, and treatment as prevention have had substantial effects on HIV-1 transmission rates, it is likely that a vaccine will be required to end the global HIV-1 epidemic.

The challenges in the development of a prophylactic HIV-1 vaccine, however, are unprecedented in the history of vaccinology. First, HIV-1 exhibits tremendous global genetic diversity as well as mutational capacity that can evade both humoral and cellular immune responses. The generation of vaccine antigens that will elicit immunologically relevant and broadly cross-reactive immune responses thus represents a major challenge. Second, HIV-1 rapidly integrates into the host genome and establishes a latent reservoir that cannot be eliminated by conventional antiretroviral drugs or virus-specific immune responses. A vaccine will therefore most likely need to induce potent and functional virus-specific antibodies that block establishment of initial infection, in addition to high levels of T lymphocytes for virologic control. Third, there are no known examples of spontaneous immune-mediated clearance of HIV-1 infection indicative of natural immunity, and thus the precise types of immune responses that need to be induced by a vaccine are not well understood. Fourth, although a series of broad and potent neutralizing monoclonal antibodies have recently been discovered, such antibodies are induced only in a subgroup of HIV-1–infected persons after several years of infection and typically exhibit extensive somatic hypermutation. No method currently exists to induce such antibodies by vaccination…

Original Article
Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine
Scott M. Hammer, M.D., Magdalena E. Sobieszczyk, M.D., M.P.H., Holly Janes, Ph.D., Shelly T. Karuna, M.D., Mark J. Mulligan, M.D., Doug Grove, M.S., Beryl A. Koblin, Ph.D., Susan P. Buchbinder, M.D., Michael C. Keefer, M.D., Georgia D. Tomaras, Ph.D., Nicole Frahm, Ph.D., John Hural, Ph.D., Chuka Anude, M.D., Ph.D., Barney S. Graham, M.D., Ph.D., Mary E. Enama, M.A., P.A.-C., Elizabeth Adams, M.D., Edwin DeJesus, M.D., Richard M. Novak, M.D., Ian Frank, M.D., Carter Bentley, Ph.D., Shelly Ramirez, M.A., Rong Fu, M.S., Richard A. Koup, M.D., John R. Mascola, M.D., Gary J. Nabel, M.D., Ph.D., David C. Montefiori, Ph.D., James Kublin, M.D., M.P.H., M. Juliana McElrath, M.D., Ph.D., Lawrence Corey, M.D., and Peter B. Gilbert, Ph.D. for the HVTN 505 Study Team
N Engl J Med 2013; 369:2083-2092November 28, 2013DOI: 10.1056/NEJMoa1310566
http://www.nejm.org/doi/full/10.1056/NEJMoa1310566

Abstract
Background
A safe and effective vaccine for the prevention of human immunodeficiency virus type 1 (HIV-1) infection is a global priority. We tested the efficacy of a DNA prime–recombinant adenovirus type 5 boost (DNA/rAd5) vaccine regimen in persons at increased risk for HIV-1 infection in the United States.

Methods
At 21 sites, we randomly assigned 2504 men or transgender women who have sex with men to receive the DNA/rAd5 vaccine (1253 participants) or placebo (1251 participants). We assessed HIV-1 acquisition from week 28 through month 24 (termed week 28+ infection), viral-load set point (mean plasma HIV-1 RNA level 10 to 20 weeks after diagnosis), and safety. The 6-plasmid DNA vaccine (expressing clade B Gag, Pol, and Nef and Env proteins from clades A, B, and C) was administered at weeks 0, 4, and 8. The rAd5 vector boost (expressing clade B Gag-Pol fusion protein and Env glycoproteins from clades A, B, and C) was administered at week 24.

Results
In April 2013, the data and safety monitoring board recommended halting vaccinations for lack of efficacy. The primary analysis showed that week 28+ infection had been diagnosed in 27 participants in the vaccine group and 21 in the placebo group (vaccine efficacy, −25.0%; 95% confidence interval, −121.2 to 29.3; P=0.44), with mean viral-load set points of 4.46 and 4.47 HIV-1 RNA log10 copies per milliliter, respectively. Analysis of all infections during the study period (41 in the vaccine group and 31 in the placebo group) also showed lack of vaccine efficacy (P=0.28). The vaccine regimen had an acceptable side-effect profile.

Conclusions
The DNA/rAd5 vaccine regimen did not reduce either the rate of HIV-1 acquisition or the viral-load set point in the population studied. (Funded by the National Institute of Allergy and Infectious Diseases; ClinicalTrials.gov number, NCT00865566.)

Contagious Diseases in the United States from 1888 to the Present

New England Journal of Medicine
November 28, 2013  Vol. 369 No. 22
http://www.nejm.org/toc/nejm/medical-journal

Medicine and Society
Contagious Diseases in the United States from 1888 to the Present
Willem G. van Panhuis, M.D., Ph.D., John Grefenstette, Ph.D., Su Yon Jung, Ph.D., Nian Shong Chok, M.Sc., Anne Cross, M.L.I.S., Heather Eng, B.A., Bruce Y. Lee, M.D., Vladimir Zadorozhny, Ph.D., Shawn Brown, Ph.D., Derek Cummings, Ph.D., M.P.H., and Donald S. Burke, M.D.
N Engl J Med 2013; 369:2152-2158November 28, 2013DOI: 10.1056/NEJMms1215400
http://www.nejm.org/doi/full/10.1056/NEJMms1215400

Summary
Using data from digitized weekly surveillance reports of notifiable diseases for U.S. cities and states for 1888 through 2011, the authors derived a quantitative history of disease reduction in the United States, focusing particularly on the effects of vaccination programs.

Devices for Low-Resource Health Care

Science        
29 November 2013 vol 342, issue 6162, pages 1013-1132
http://www.sciencemag.org/current.dtl

Perspective
Engineering
Devices for Low-Resource Health Care
Rebecca Richards-Kortum, Maria Oden
Bioengineering Department, Rice University, 6100 Main Street, Houston, TX 77005, USA.
http://www.sciencemag.org/content/342/6162/1055.summary

Summary
Most of the world receives health care in low-resource settings (see the figure), yet medical technologies are designed to be used mainly in high-resource settings, where designers take for granted basic infrastructure that supports their safe use and effective distribution. The corridors of many hospitals in low-resource settings are lined with donated medical equipment, but up to three-quarters of these devices do not work, often due to lack of spare parts or consumables (1). As a result, most of the world’s population lacks access to life-saving technologies developed decades ago, including infant incubators, oxygen concentrators, and simple laboratory diagnostics. In this Perspective, we review the challenges of developing and translating medical technologies and highlight promising new technologies to improve health in low-resource settings.

TUBERCULOSIS TB or Not TB: That Is No Longer the Question

Science Translational Medicine
27 November 2013 vol 5, issue 213
http://stm.sciencemag.org/content/current

TUBERCULOSIS
TB or Not TB: That Is No Longer the Question
Robert L. Modlin and Barry R. Bloom
27 November 2013: 213sr6
http://stm.sciencemag.org/content/5/213/213sr6.abstract

Summary
Tuberculosis (TB) remains a devastating infectious disease and, with the emergence of multidrug-resistant forms, represents a major global threat. Much of our understanding of pathogenic and immunologic mechanisms in TB has derived from studies in experimental animals. However, it is becoming increasingly clear in TB as well as in other inflammatory diseases that there are substantial differences in immunological responses of humans not found or predicted by animal studies. Thus, it is critically important to understand mechanisms of pathogenesis and immunological protection in humans. In this review, we will address the key immunological question: What are the necessary and sufficient immune responses required for protection against TB infection and disease in people—specifically protection against infection, protection against the establishment of latency or persistence, and protection against transitioning from latent infection to active disease.

Third European Influenza Summit: Organized by the European Scientific Working group on Influenza (ESWI)

Vaccine
http://www.sciencedirect.com/science/journal/0264410X
Volume 31, Issue 52, Pages 6161-6266 (16 December 2013)

Third European Influenza Summit: Organized by the European Scientific Working group on Influenza (ESWI)
Pages 6161-6167
Janet McElhaney, Ab. Osterhaus
Abstract
On 2 May 2013, the European Scientific Working group on Influenza (ESWI) held its third influenza summit at the Institute of European Studies at the Free University of Brussels. ESWI brought together more than 90 representatives of organizations of healthcare providers, senior citizens, at-risk patients and public health authorities for a day of tailored lectures, Q&A sessions and networking. Since recent studies, surveys and reviews have shed new light on some of the most intriguing influenza issues, the Summit faculty translated the newest scientific data into practice. The first part of the Summit programme focused on the current flu status in Europe, paying special attention to the protection of pregnant women and the elderly as well as to the issues of vaccine safety and effectiveness. The programme continued to highlight future challenges and evolutions like novel antiviral drugs against influenza, improved flu vaccines and the prospect of a universal flu vaccine. The annual ESWI flu summits are the pinnacles of ESWI’s efforts to bridge the gap between science and society. ESWI’s members are convinced that the fight against influenza can only be won when all parties are well informed and ready to work together.

Ethical analyses of institutional measures to increase health care worker influenza vaccination rates

Vaccine
http://www.sciencedirect.com/science/journal/0264410X
Volume 31, Issue 52, Pages 6161-6266 (16 December 2013)

Ethical analyses of institutional measures to increase health care worker influenza vaccination rates
Review Article
Pages 6172-6176
Richard K. Zimmerman

Abstract
Health care worker (HCW) influenza vaccination rates are modest. This paper provides a detailed ethical analysis of the major options to increase HCW vaccination rates, comparing how major ethical theories would address the options. The main categories of interventions to raise rates include education, incentives, easy access, competition with rewards, assessment and feedback, declination, mandates with alternative infection control measures, and mandates with administrative action as consequences.

The aforementioned interventions, except mandates, arouse little ethical controversy. However, these efforts are time and work intensive and rarely achieve vaccination rates higher than about 70%. The primary concerns voiced about mandates are loss of autonomy, injustice, lack of due process, and subsuming the individual for institutional ends. Proponents of mandates argue that they are ethical based on beneficence, non-maleficence, and duty. A number of professional associations support mandates. Arguments by analogy can be made by mandates for HCW vaccination against other diseases.

The ethical systems used in the analyses include evolutionary ethics, utilitarianism, principalism (autonomy, beneficence, non-maleficence, and justice), Kantism, and altruism. Across these systems, the most commonly preferred options are easy access, assessment and feedback, declinations, and mandates with infection control measures as consequences for non-compliance.

Given the ethical imperatives of non-maleficence and beneficence, the limited success of lower intensive interventions, and the need for putting patient safety ahead of HCW convenience, mandates with additional infection control measures as consequences for non-compliance are preferred. For those who opt out of vaccination due to conscience concerns, such mandates provide a means to remain employed but not put patient safety at risk.

The role of health economic analyses in vaccine decision makin

Vaccine
Volume 31, Issue 51, Pages 6041-6160 (9 December 2013)
http://www.sciencedirect.com/science/journal/0264410X/31/51

The role of health economic analyses in vaccine decision making
Review Article
Pages 6046-6049
Steven Black
Abstract
Beginning in the 20th century with the consideration of the seven-valent pneumococcal conjugate vaccine in the US, the cost effectiveness became a topic of discussion when this vaccine was being considered for universal use by the US Advisory Committee on Immunization practices (ACIP). In 2008, the ACIP began using formal criteria for the presentation of such data and their inclusion in ACIP discussions. More recently, the US Institute of Medicine has recommended that health economic considerations play a primary role in the prioritization of future vaccine for development. However, such analyses can be biased towards vaccines that provide economic benefit rather than those that reduce severe morbidity and mortality. This is because the economic impact of minor common events that result in medical utilization or time lost from work for parents can outweigh the economic impact of severe morbidity and mortality.    Thus diseases with a low mortality and morbidity but with a common clinical manifestation such as the common cold could be prioritized over vaccines against diseases such as meningococcal sepsis where the morbidity and mortality associated with each case is very high, but there is no associated common clinical syndrome. Thus the use of cost effectiveness analyses as a ‘gating criteria’ to decide which vaccines should be developed or routinely used runs the risk of transforming vaccines into primarily a tool for achieving cost savings within the health care system rather than a public health intervention targeting human suffering, death and disability.    It is the purpose of this article to review the framework under which health economic evaluations can be undertaken, to review the experience with and reliability of such analyses, and to discuss the potential negative implications of the use of health economic analyses as a primary decision making tool.

Using solar-powered refrigeration for vaccine storage where other sources of reliable electricity are inadequate or costly

Vaccine
Volume 31, Issue 51, Pages 6041-6160 (9 December 2013)
http://www.sciencedirect.com/science/journal/0264410X/31/51

Using solar-powered refrigeration for vaccine storage where other sources of reliable electricity are inadequate or costly
Review Article
Pages 6050-6057
Steve McCarney, Joanie Robertson, Juliette Arnaud, Kristina Lorenson, John Lloyd

Abstract
Large areas of many developing countries have no grid electricity. This is a serious challenge that threatens the continuity of the vaccine cold chain. The main alternatives to electrically powered refrigerators available for many years—kerosene- and gas-driven refrigerators—are plagued by problems with gas supply interruptions, low efficiency, poor temperature control, and frequent maintenance needs. There are currently no kerosene- or gas-driven refrigerators that qualify under the minimum standards established by the World Health Organization (WHO) Performance, Quality, and Safety (PQS) system.

Solar refrigeration was a promising development in the early 1980s, providing an alternative to absorption technology to meet cold chain needs in remote areas. Devices generally had strong laboratory performance data; however, experience in the field over the years has been mixed. Traditional solar refrigerators relied on relatively expensive battery systems, which have demonstrated short lives compared to the refrigerator. There are now alternatives to the battery-based systems and a clear understanding that solar refrigerator systems need to be designed, installed, and maintained by technicians with the necessary knowledge and training. Thus, the technology is now poised to be the refrigeration method of choice for the cold chain in areas with no electricity or extremely unreliable electricity (less than 4 h per average day) and sufficient sunlight.

This paper highlights some lessons learned with solar-powered refrigeration, and discusses some critical factors for successful introduction of solar units into immunization programs in the future including:

:: Sustainable financing mechanisms and incentives for health workers and technicians are in place to support long-term maintenance, repair, and replacement parts.

:: System design is carried out by qualified solar refrigerator professionals taking into account the conditions at installation sites.

:: Installation and repair are conducted by well-trained technicians.

:: Temperature performance is continuously monitored and protocols are in place to act on data that indicate problems.

Coverage and cost of a large oral cholera vaccination program in a high-risk cholera endemic urban population in Dhaka, Bangladesh

Vaccine
Volume 31, Issue 51, Pages 6041-6160 (9 December 2013)
http://www.sciencedirect.com/science/journal/0264410X/31/51

Coverage and cost of a large oral cholera vaccination program in a high-risk cholera endemic urban population in Dhaka, Bangladesh
Original Research Article
Pages 6058-6064
Iqbal Ansary Khan, Amit Saha, Fahima Chowdhury, Ashraful Islam Khan, Md Jasim Uddin, Yasmin A. Begum, Baizid Khoorshid Riaz, Sanjida Islam, Mohammad Ali, Stephen P. Luby, John D. Clemens, Alejandro Cravioto, Firdausi Qadri
Abstract
A feasibility study of an oral cholera vaccine was carried out to test strategies to reach high-risk populations in urban Mirpur, Dhaka, Bangladesh. The study was cluster randomized, with three arms: vaccine, vaccine plus safe water and hand washing practice, and no intervention. High risk people of age one year and above (except pregnant woman) from the two intervention arms received two doses of the oral cholera vaccine, Shanchol™. Vaccination was conducted between 17th February and 16th April 2011, with a minimum interval of fourteen days between two doses. Interpersonal communication preceded vaccination to raise awareness amongst the target population. The number of vaccine doses used, the population vaccinated, left-out, drop out, vaccine wastage and resources required were documented. Fixed outreach site vaccination strategy was adopted as the mode of vaccine delivery. Additionally, mobile vaccination sites and mop-up activities were carried out to reach the target communities. Of the 172,754 target population, 141,839 (82%) and 123,666 (72%) received complete first and second doses of the vaccine, respectively. Dropout rate from the first to the second dose was 13%. Two complete doses were received by 123,661 participants. Vaccine coverage in children was 81%. Coverage was significantly higher in females than in males (77% vs. 66%, P < 0.001). Vaccine wastage for delivering the complete doses was 1.2%. The government provided cold-chain related support at no cost to the project. Costs for two doses of vaccine per-person were US$3.93, of which US$1.63 was spent on delivery. Cost for delivering a single dose was US$0.76. We observed no serious adverse events. Mass vaccination with oral cholera vaccine is feasible for reaching high risk endemic population through the existing national immunization delivery system employed by the government.

Cost-effectiveness of a new rotavirus vaccination program in Pakistan: A decision tree model

Vaccine
Volume 31, Issue 51, Pages 6041-6160 (9 December 2013)
http://www.sciencedirect.com/science/journal/0264410X/31/51

Cost-effectiveness of a new rotavirus vaccination program in Pakistan: A decision tree model
Original Research Article
Pages 6072-6078
Hiten D. Patel, Eric T. Roberts, Dagna O. Constenla
Abstract
Background
Rotavirus gastroenteritis places a significant health and economic burden on Pakistan. To determine the public health impact of a national rotavirus vaccination program, we performed a cost-effectiveness study from the perspective of the health care system.

Methods
A decision tree model was developed to assess the cost-effectiveness of a national vaccination program in Pakistan. Disease and cost burden with the program were compared to the current state. Disease parameters, vaccine-related costs, and medical treatment costs were based on published epidemiological and economic data, which were specific to Pakistan when possible. An annual birth cohort of children was followed for 5 years to model the public health impact of vaccination on health-related events and costs. The cost-effectiveness was assessed and quantified in cost (2012 US$) per disability-adjusted life-year (DALY) averted and cost per death averted. Sensitivity analyses were performed to assess the robustness of the incremental cost-effectiveness ratios (ICERs).

Results
The base case results showed vaccination prevented 1.2 million cases of rotavirus gastroenteritis, 93,000 outpatient visits, 43,000 hospitalizations, and 6700 deaths by 5 years of age for an annual birth cohort scaled from 6% current coverage to DPT3 levels (85%). The medical cost savings would be US$1.4 million from hospitalizations and US$200,000 from outpatient visit costs. The vaccination program would cost US$35 million at a vaccine price of US$5.00. The ICER was US$149.50 per DALY averted or US$4972 per death averted. Sensitivity analyses showed changes in case–fatality ratio, vaccine efficacy, and vaccine cost exerted the greatest influence on the ICER.

Conclusions
Across a range of sensitivity analyses, a national rotavirus vaccination program was predicted to decrease health and economic burden due to rotavirus gastroenteritis in Pakistan by ∼40%. Vaccination was highly cost-effective in this context. As discussions of implementing the intervention intensify, future studies should address affordability, efficiency, and equity of vaccination introduction.

Evaluation of several approaches to immunize parents of neonates against B. pertussis

Vaccine
Volume 31, Issue 51, Pages 6041-6160 (9 December 2013)
http://www.sciencedirect.com/science/journal/0264410X/31/51

Evaluation of several approaches to immunize parents of neonates against B. pertussis
Original Research Article
Pages 6087-6091
Julie Frère, Philippe De Wals, Philippe Ovetchkine, Léna Coïc, François Audibert, Bruce Tapiero
Abstract
Background
Parental immunization (“cocooning”) is a potentially effective strategy to protect neonates against Bordetella pertussis. The objective of this study was to evaluate three approaches to parental immunization: (1) current practice (single dTap dose to adolescents, one additional dose recommended in adults); (2) promotion of vaccination in the maternity ward, with vaccine offered in the community; and (3) promotion and administration of vaccine in the maternity ward.

Methods
We conducted a two-phase study of postpartum women in a tertiary care obstetric–pediatric hospital in Montreal, Canada. In Phase I, mothers completed a standardized questionnaire regarding pertussis knowledge, attitudes and immunization status. Interviews provided information on cocooning and pertussis vaccination, and invited parents to receive the vaccine in the community. In phase II, information was provided (no questionnaire) with vaccination offered in the maternity ward before discharge.

Results
Phase I included 101 participants; Phase II, 244. Baseline knowledge on infant disease severity and adult vaccine recommendations was poor. Only 6% of women were considered protected. In Phase I, 56.3% and 62.5% of eligible mothers and fathers, respectively, were willing to receive the vaccine; only 5.4% and 8.7% were immunized in the community. In Phase II, 53.1% and 62.6% of mothers and fathers, respectively, would accept vaccination; 46.9% of mothers and 60.5% of fathers were immunized onsite (p < 0.01).

Conclusion
Offering dTap vaccine in the maternity ward is an effective approach to promote cocooning and increase vaccine uptake. The generalizability and cost effectiveness of this strategy should be investigated further.

Long-term clinical studies of varicella vaccine at a regional hospital in Japan and proposal for a varicella vaccination program

Vaccine
Volume 31, Issue 51, Pages 6041-6160 (9 December 2013)
http://www.sciencedirect.com/science/journal/0264410X/31/51

Long-term clinical studies of varicella vaccine at a regional hospital in Japan and proposal for a varicella vaccination program
Review Article
Pages 6155-6160
Takao Ozaki
Abstract
In 1974, a live varicella vaccine (Oka strain) was developed in Japan for the prevention of varicella. It has been commercially available since 1987 for the voluntary vaccination program, in which children over the age of 1 year with no history of previous varicella infection receive a single dose. From before approval up to the present, we have been carrying out long-term studies in healthy children at a regional hospital to assess the immunogenicity, safety, and efficacy of the varicella vaccine. This vaccine is very safe, and serious adverse reactions have not been observed since the year 2000 when it changed gelatin-free. In the past three studies, seroconversion was detected in around 95% of subjects by the immune adherence hemagglutination (IAHA) test, and this high rate was considered to indicate good immunogenicity. Breakthrough varicella is observed in approximately 20–30% of children who receive a single dose of the vaccine, but most cases are mild.

Although recent vaccination has generally been effective, the IAHA test has shown that immunogenicity is somewhat lower than was previously demonstrated. The sensitivity of the IAHA test has been shown to be adequate when compared with the neutralization test, so the current testing system is sufficient for the maintenance of immunity levels. An additional vaccination increased the IAHA antibody level in subjects who failed to seroconvert after a single dose vaccination. According to another clinical study, additional varicella vaccination at 3–5 years after the initial vaccination achieved stronger immunogenicity.

Because it is administered as part of the voluntary vaccination program, the varicella vaccination coverage rate has remained low in Japan, with no sign of a decrease in the number of varicella patients. We consider that implementation of routine varicella vaccination program based on the Preventive Vaccination Law would be the most effective approach for improvement of the coverage rate. Along with this, introduction of a two-dose schedule would also be desirable. In addition to decreasing the prevalence of characteristic breakthrough varicella infection, the vaccination coverage rate would also be expected to improve with a two-dose schedule due to an increase in opportunities for vaccination.

What Parents and Adolescent Boys Want in School Vaccination Programs in the United States

From Google Scholar & other sources: Selected Journal Articles, Newsletters, Dissertations, Theses, Commentary

Journal of Adolescent Health
Available online 26 November 2013
What Parents and Adolescent Boys Want in School Vaccination Programs in the United States
PD Shah, AL McRee, PL Reiter, NT Brewer –
http://www.sciencedirect.com/science/article/pii/S1054139X13005211
Abstract
Purpose
Schools are increasingly a part of vaccine provision, because of laws mandating provision of information by schools about vaccination, school entry requirements, and mass vaccination campaigns. We examined preferences for programmatic aspects of voluntary school mass vaccination programs (i.e., “vaccination days”).

Methods
We analyzed data from a national sample of United States parents of adolescent males ages 11–19 years (n=308) and their sons (n=216), who completed an online survey in November 2011.

Results
Sons believed that adolescents should be able to get vaccinated without parental consent at a younger age than parents did (p<.001) and were more willing to participate in vaccination days without a parent present (p=.04). Parents perceived school vaccination days to be a more convenient way to get their sons recommended vaccines if they were younger parents, had older adolescent sons, supported laws letting schools share vaccination records with health care providers, or had sons who were previously immunized at school (all p < .05). Parents of older sons were less likely to want their sons’ vaccination records sent home (odds ratio [OR]=.47; 95% confidence interval [CI], .29-.77) or to their sons’ physicians (OR = .61; 95% CI, .37-.98) compared with parents of younger sons, but more likely to prefer their sons’ records be entered in an immunization registry (OR=1.66; 95% CI, 1.05-2.63).

Conclusions
Sons’ age had an important role in support for vaccination days and preferences for sharing vaccination information with health care professionals. Parents and sons had similar beliefs about vaccination in schools, but the sons’ responses suggested an interest in greater autonomy.

cfr: Wired – The Surge [Polio eradication]

Council on Foreign Relations
http://www.cfr.org/
Accessed 30 November 2013

Wired: The Surge [Polio eradication]
http://www.cfr.org/health/wired-surge/p31963
Matthieu Aikins
November 26, 2013
Excerpt
“Once you have beaten back a disease to just a few hundred cases, they will almost by definition be concentrated in places where there’s some barrier—geographical, cultural, political—to easy vaccination. In general, each marginal case will cost more, and will consume more time and effort and labor, than the one before it…[but] the math of cost-benefit analy­ses runs aground when it comes to eradication campaigns, because the benefits, in theory, are infinite.”

In 1988 there were 350,000 cases of polio worldwide. Last year there were 223. But getting all the way to zero will mean spending billions of dollars, penetrating the most remote regions of the globe, and facing down Taliban militants to get to the last unprotected children on earth.

The border regions between Pakistan and Afghanistan are wracked by violence, and their rural hinterlands are largely under the control of a diverse array of militant groups. The Taliban in Afghanistan have been mostly cooperative with the polio campaign–in the south of the contry, where their writ is strongest, they even help point out areas missed by vaccine teams–but in 2012 Taliban leaders in Pakistan began banning vaccinations in their areas, condemning the campaign as an American plot. They also started targeting campaign workers for assassination: Since the ban started, 22 people have been killed in attacks on vaccine teams…

Vaccines and Global Health: The Week in Review 23 Nov 2013

Vaccines and Global Health: The Week in Review is a weekly digest — summarizing news, events, announcements, peer-reviewed articles and research in the global vaccine ethics and policy space. Content is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage. You are viewing the blog version of our weekly digest, typically comprised of between 30 and 40 posts below all dated “29 June 2013″
.
Email Summary: Vaccines and Global health : The Week in Review is published as a single email summary, scheduled for release each Saturday eveningbefore midnight (EDT in the U.S.). If you would like to receive the email version, please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.
.
pdf version: A pdf of the current issues is available here: Vaccines and Global Health_The Week in Review_23 Nov 2013
.
Twitter: Readers can also follow developments on twitter: @vaxethicspolicy.
.
Links: We endeavor to test each link as we incorporate it into any post, but recognize that some links may become “stale” as publications and websites reorganize content over time. We apologize in advance for any links that may not be operative. We believe the contextual information in a given post should allow retrieval, but please contact us as above for assistance if necessary.
.
Support: If you would like to join the growing list of individuals who support this service and its contribution to their roles in public health, clinical practice, government, IGOs/NGOs, research, industry and academia, please visit this page at The Wistar Institute, our co-founder and fiduciary. Thank you…
.
David R. Curry, MS
Executive Director
Center for Vaccine Ethics and Policy
a program of the
– Division of Medical Ethics, NYU Medical School
– The Wistar Institute Vaccine Center
– Children’s Hospital of Philadelphia Vaccine Education Center
Associate Faculty, Division of Medical Ethics, NYU Medical School

WHO and the Philippine Government launch mass vaccination campaign

News release: WHO and the Philippine Government launch mass vaccination campaign
22 November 2013
Excerpt
MANILA, Philippines – WHO and the Philippine Department of Health have launched a vaccination campaign to prevent outbreaks of measles and polio among survivors of Typhoon Haiyan (Yolanda)…The campaign targets children in areas hardest hit by the disaster – starting with the evacuation centres in the city of Tacloban and at receiving centres in Cebu, where evacuated families are finding temporary shelter. Children under 5 years old are being vaccinated against polio and measles and given Vitamin A drops to boost their immune systems. ..WHO worked with the Department of Health to finalize plans and procure all necessary vaccines and supplies to carry out the campaign and set up immunization stations…WHO is working with partners to arrange for the delivery of vaccines using gas-powered and generator-powered fridges, freezers, vaccine-cases, cold boxes and ice packs for affected areas that have lost power. This “cold chain” is necessary to keep the vaccines from being spoiled. USAID has sent 6 solar-powered refrigerators to Tacloban.
http://www.who.int/mediacentre/news/releases/2013/philippines-vaccination-20131122/en/index.html

WHO – Humanitarian Health Action
http://www.who.int/hac/en/index.html
WHO responding to health needs caused by typhoon Haiyan (Yolanda) 2013 – Health Cluster Bulletin – 20 November 2013

GAVI Alliance Board decisions, Phnom Penh, Cambodia meeting, November 2013

The GAVI Alliance Board, meeting in Phnom Penh, Cambodia, took a number of decisions on additional vaccines for the Alliance’s future portfolio, having received detailed analysis on five disease areas as part of the Vaccine Investment Strategy. The Board:
:: Decided new support would be made available for additional yellow fever campaigns in light of a resurgence of the disease in some parts of Africa.
:: Approved a contribution towards a global cholera vaccine stockpile for the period 2014-2018 to increase access to oral cholera vaccine in outbreak situations and endemic settings.
:: Agreed to continue to consider support for a malaria vaccine if and when one is licensed, prequalified by the WHO and recommended for use by the joint meeting of the WHO Strategic Advisory Group of Experts (SAGE) and the Malaria Programme Advisory Committee (expected in 2015), taking into account updated projections of impact, cost and country demand.
:: Concluded that further evidence is necessary on the impact and operational feasibility of supporting the important rabies vaccine as well as influenza vaccines for pregnant women. The Board agreed that GAVI will fund an observational study to address critical knowledge gaps around access to rabies vaccine and will monitor the evolving evidence base for maternal influenza vaccination in coming years.
Full media Release:  Phnom Penh, 22 November 2013 –   http://www.gavialliance.org/library/news/press-releases/2013/gavi-alliance-to-support-introduction-of-inactivated-polio-vaccine-in-worlds-73-poorest-countries/

Polio [to 23 Nove,ber 2013]

    The GAVI Alliance Board approved providing support for the introduction of inactivated poliovirus vaccine (IPV) as part of routine immunisation programmes in the world’s 73 poorest countries.  GAVI noted that in May 2013, the World Health Assembly endorsed the new Polio Eradication & Endgame Strategic Plan 2013-2018, “calling on countries to introduce at least one dose of IPV and begin the phased removal of oral polio vaccines. Removing oral polio vaccines will eliminate the risk of vaccine-associated polio outbreaks.  Introducing IPV is a critical step to manage any risks associated with this phased removal. Adding IPV to routine immunisation programmes will improve immunity and help prevent new vaccine-associated outbreaks from emerging. At the same time, it will hasten eradication of wild polio serotypes in the remaining endemic countries of Afghanistan, Nigeria and Pakistan….”
The GAVI Board “endorsed opening a window of support for IPV for all GAVI-eligible countries and those graduating from GAVI support. Given the global health priority of polio eradication, the Board agreed to a number of policy exceptions for IPV, such as encouraging but not requiring countries to co-finance IPV introduction.”

   The Jeffrey Modell Foundation (JMF) announced “an unprecedented surveillance study…to shed light on important questions about vaccine-derived polioviruses throughout the globe…” This study will include 25 sites across a wide geographical range involving  patient population for this surveillance, including JMF Centers in Argentina, Brazil, Colombia, Mexico, China, Hong Kong, India, Israel, Iran, Kuwait, Russia, Poland, Turkey and Tunisia. JMF “will work alongside the World Health Organization (WHO), The Centers for Disease Control and Prevention (CDC), Task Force for Global Health (TFGH), and the Bill & Melinda Gates Foundation.” The study will ”…focus on patients with Primary Immunodeficiencies (PI) who have either received the Oral Polio Vaccine (OPV), a live-weakened form of the virus, or have been exposed to it. Due to little or no immune system, when a patient with PI receives OPV, he or she is unable to create an immune response and therefore, cannot clear the intestinal vaccine virus infection, which is typically excreted within six to eight weeks by individuals with healthy immune systems. After prolonged periods of time, the virus may no longer be the same as the original vaccine-virus as it can genetically alter. This is called Vaccine Derived Poliovirus (VDPV). Although rare, it is expected that patients with PI are at risk of developing Vaccine Associated Paralytic Poliomyelitis (VAPP) and VDPV excretion, which could lead to possible exposure to the community…Once wild poliovirus is eradicated globally, vaccine-viruses will be the only type of live poliovirus in the community and could potentially lead to an outbreak. In order to prevent this occurrence, the Polio Antivirals Initiative (PAI), an essential part of the TFGH’s Polio Eradication effort, aims to create an efficient and inexpensive antiviral.”
More information about PI: www.info4pi.org
Full media release: NEW YORK, Nov. 18, 2013 /PRNewswire/   http://www.prnewswire.com/news-releases/global-polio-study-begins-232335041.html

WHO: Global Alert and Response (GAR) – Disease Outbreak News
http://www.who.int/csr/don/2013_03_12/en/index.html
:: Middle East respiratory syndrome coronavirus (MERS-CoV) – update 18 November 2013
:: Wild poliovirus in Cameroon 21 November 2013
Excerpt
21 November 2013 – Wild poliovirus type 1 (WPV1) has been confirmed in Cameroon, the first wild poliovirus in the country since 2009. Wild poliovirus was isolated from two acute flaccid paralysis (AFP) cases from West Region. The patients developed paralysis on 1 October and 19 October 2013. Genetic sequencing indicates that these viruses are linked to wild poliovirus last detected in Chad in 2011.
An emergency outbreak response plan is being finalized, including at least three national immunization days (NIDs), the first of which was conducted on 25-27 October 2013. Subnational immunization days (SNIDs) will be implemented in December 2013, followed by two subsequent national immunization days in January and February 2014. Routine immunization rates are reported to be approximately 85.3 percent for oral polio vaccine (OPV3).      A response in neighbouring countries is also being planned, notably in Chad and Central African Republic…
…This event confirms the risk of ongoing international spread of a pathogen (wild poliovirus) slated for eradication. Given the history of international spread of polio from northern Nigeria across West and Central Africa and subnational surveillance gaps, WHO assesses the risk of further international spread across the region as high…
http://www.who.int/csr/don/2013_11_21/en/index.html

Update: Polio this week – As of 23 November 2013
Global Polio Eradication Initiative
Full report: http://www.polioeradication.org/Dataandmonitoring/Poliothisweek.aspx
[Editor’s extract and bolded text]
:: In the Middle East, a comprehensive outbreak response continues to be implemented across the region. Seven countries and territories are holding mass polio vaccination campaigns targeting 22 million children under the age of five years. In a joint resolution, all countries of the WHO Eastern Mediterranean Region have declared polio eradication to be an emergency, calling for support in negotiating and establishing access to those children who are currently unreached with polio vaccination. WHO and UNICEF are committed to working with all organizations and agencies providing humanitarian assistance to Syrians affected by the conflict. This includes vaccinating all Syrian children no matter where they are, whether in government or contested areas, or outside Syria.
:: In southern Afghanistan, the traditional endemic region in the country, no WPV cases have been reported for one year. All nine cases in the country this year are from Eastern Region, linked to cross-border transmission with Pakistan. For more, please click here.

Pakistan
:: Four new WPV1 cases were reported in the past week. Two of the cases are from Federally Administered Tribal Areas (FATA), one from Punjab and one from Sindh. The total number of WPV1 cases for Pakistan in 2013 is now 63. The most recent WPV1 case had onset of paralysis on 21 October (from Punjab).
:: The situation in North Waziristan is increasingly alarming. It is the area with the largest number of children being paralyzed by poliovirus in all of Asia. Immunization activities have been suspended by local leaders since June 2012. It is critical that children in these areas are vaccinated and protected from poliovirus. Immunizations in neighboring high-risk areas are being intensified, to further boost population immunity levels in those areas and prevent further spread of this outbreak.

Horn of Africa
:: Three new WPV1 cases were reported in the past week (from Somalia), bringing the total number of WPV1 cases in the Horn of Africa to 203 (183 from Somalia, 14 from Kenya and six from Ethiopia). The most recent WPV1 case in the region had onset of paralysis on 9 October (from Lower Shabelle, Somalia).
:: Outbreak response across the Horn of Africa is continuing. As a result of concerted outbreak response efforts, the impact of the response is beginning to be seen, as the number of newly-reported cases from Banadir, Somalia (the epicentre of the outbreak) has declined. All efforts continue to be made to reach all children everywhere.

Middle East
:: In Syria, no new WPV1 cases were reported in the past week. The total number of WPV1 cases remains 13. Wild poliovirus was last reported in Syria in 1999.
:: A comprehensive outbreak response continues to be implemented across the region. On 24 October, an already-planned large-scale supplementary immunization activity was launched in Syria to vaccinate 1.6 million children against polio, measles, mumps and rubella, in both government-controlled and contested areas.
:: Implementation of a supplementary immunization campaign in Deir Al Zour province commenced promptly when the first ‘hot’ acute flaccid paralysis (AFP) cases were reported .

Editor’s Note: See New England Journal of Medicine below in Journal Watch:
Editorial
No Country Is Safe without Global Eradication of Poliomyelitis
Trevor Mundel, M.D., Ph.D., and Walter A. Orenstein, M.D.
Original Article
Identification and Control of a Poliomyelitis Outbreak in Xinjiang, China
Hui-Ming Luo, M.D et al

The Weekly Epidemiological Record (WER) for 22 November 2013, vol. 88, 47 (pp. 501–508) includes:
:: Progress towards poliomyelitis eradication in Pakistan, January 2012– September 2013
http://www.who.int/entity/wer/2013/wer8847.pdf

CDC/MMWR Watch [to 23 November 2013]
A serogroup B meningococcal vaccine is being considered for use at Princeton University. FDA is allowing the use of the vaccine at Princeton University under an Investigational New Drug application. Get the latest information and additional questions and answers about the outbreak from the University and the New Jersey Department of Health  [9 pages]
   MMWR November 22, 2013 / Vol. 62 / No. 46
:: Progress Toward Poliomyelitis Eradication — Afghanistan, January 2012–September 2013
:: Progress Toward Poliomyelitis Eradication — Pakistan, January 2012–September 2013

FDA approves first adjuvanted vaccine for H5N1

    The U.S. Food and Drug Administration approved the first adjuvanted vaccine for the prevention of H5N1 influenza: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted is for use in people 18 years of age and older who are at increased risk of exposure to the H5N1 influenza virus. The H5N1 avian influenza vaccine “is not intended for commercial availability. The U.S. Department of Health and Human Services has purchased the vaccine from the manufacturer, ID Biomedical Corporation of Quebec, Quebec City, Canada (a subsidiary of GlaxoSmithKline Biologicals), for inclusion within the National Stockpile for distribution by public health officials if needed.”
Full FDA NEWS RELEASE, Nov. 22, 2013:

National Routine Immunization Strategic Plan (NRISP) 2013-2015

 Nigeria unveiled its National Routine Immunization Strategic Plan (NRISP) 2013-2015, “outlining a comprehensive strategy to increase access to live-saving vaccines through strengthened routine immunization (RI) systems.” The plan was co-launched by the Nigerian Minister of Health, Prof. Onyebuchi Chukwu and Mr. Bill Gates in an event hosted by the National Primary Health Care Development Agency (NPHCDA) and attended by traditional and religious leaders, private sector representatives, and development partners, including Alhaji Aliko Dangote and the Sultan of Sokoto.
http://www.jhsph.edu/research/centers-and-institutes/ivac/about-us/news.html#Nigeria_NRISP_launch_2013

National Routine Immunization Strategic Plan (NRISP) 2013-2015
Executive Summary
This National Routine Immunization Strategic Plan (NRISP) lays out key goals and objectives for Nigeria’s routine immunization (RI) system, and details the strategies that will allow the country to achieve its aims, while recognizing important challenges.

NRISP is not a standalone document, instead it was developed to fit within the National Strategic Health Development Plan 2010-2015 (NSHDP) and expand upon the comprehensive Multi-Year Plan 2011-2015 (cMYP). The NRISP will also operate within and alongside Nigeria’s Saving One Million Lives Initiative (SOML) and other efforts to meet the MDGs. As highlighted in these initiatives, the NRISP is guided by a set of core principles, namely: accountability, efficiency, equity, ownership, integration, sustainability, and transparency.

Within the NRISP, the Strategic Framework enumerates strategies to improve the country’s RI system. Three strategic focal areas have been identified to concentrate efforts to improve the system in practice; these strategies are already in place to varying extents and are recognizable by stakeholders at all levels in Nigeria. They are: Reaching Every Ward (REW), Accountability for RI Framework (AFRIN), and Health System Strengthening.

The Strategic Framework’s strategies are categorized into RI system areas, and outputs, indicators, and responsible parties have been developed for each. A monitoring and evaluation (M&E) process describes a regular reporting structure inclusive of relevant stakeholders, and seeks to ensure that data are available in a timely manner and used in decision making. A system of rewards and sanctions are also suggested to improve accountability.

The NRISP aims to clarify the roles and responsibilities for different levels of government in the execution of the RI system. The National Primary Health Care Development Agency (NPHCDA)and partners are responsible for providing policy direction, mobilizing resources to fill gaps, building capacity, providing supportive supervision, and conducting M&E of the RI program. Implementation of this strategic plan and accountability framework will fall on the shoulders of states and local government areas (LGAs). The expectation is that State Primary Health Care Development Agencies (SPHCDAs) will guide LGAs, and LGAs will in turn support health facilities (HFs).

Consequent upon the above, the total budget to implement this plan for the period July 2013 to December 2015 estimated at USD 642,038,476 has been shared among the three tiers of governments. Therefore, 69% will be the responsibility of the federal, 15% that of the states, and 16% will be borne by the local governments. This averages USD 35.41 per child born in Nigeria over the next two and a half years.

Finally, the NRISP was developed through a consultative process that included stakeholders from all levels of government and various facets of society. Commitments were made on behalf of MoH, NPHCDA, states, and other important institutions to take up and implement these recommendations for the unanimously agreed upon purpose of this strategy: protecting the health of Nigeria’s children through equitable provision of RI.

New “blue marble health” framework for NTDs

Media Release: New framework for neglected tropical diseases could unlock potential for world’s poorest people
22 November 2013

Excerpt
A new concept and policy framework published in PLOS NTDs outlines concrete steps for  the global development community as it works to synthesize health goals with economic, environmental and social priorities. The concept, “blue marble health,” emphasizes the role of the Group of 20 (G20) nations in tackling neglected tropical diseases (NTDs) to expedite poverty reduction efforts. Peter Hotez, MD PhD, president of the Sabin Vaccine Institute, director of the Sabin Vaccine Institute and Texas Children’s Hospital Center for Vaccine Development and dean of the National School of Tropical Medicine at Baylor College of Medicine, said “Blue marble health connects countries worldwide by recognizing that extreme poverty is a fundamental underlying factor for neglected tropical diseases (NTDs), regardless of where they occur. G20 countries have an exceptional opportunity to embrace NTD control as a cross-cutting strategy and achieve long-lasting, inclusive prosperity within their societies and lower-income countries.”…
…Existing medicines for the seven most common NTDs are safe, effective, and inexpensive. However, new tools and diagnostics will help us stay ahead of how current treatment needs evolve and enable us to address several NTDs for which there are no current options available. G20 countries have an important role to play in investing in R&D, including building up the local capacity of vaccine manufacturers in disease-endemic countries:
:: Vaccine Diplomacy: Promoting scientific collaboration between institutions from countries regardless of their ideological perspectives can foster essential dialogue on these life-threatening diseases and lead to new, effective interventions.
:: NTD Integration: Strong linkages exist between NTDs and nearly every major development priority. Efforts to control and eliminate should be incorporated into existing programs working to improve maternal and child health; water, sanitation and hygiene; hunger and nutrition; education; and combat HIV/AIDS, tuberculosis and malaria.
:: Health of Girls and Women: This population is especially disproportionately affected – indeed NTDs may be the most common afflictions of girls and women living in poverty.
:: NCDs: NTDs contribute to a hidden but substantial proportion of the world’s non-communicable diseases.
:: Sustainable Development Goals (SDGs): Controlling NTDs will serve as a catalyst for the achievement of the Millennium Development Goals and a broad set of issues likely to be addressed in the new SDGs. It will be essential to incorporate NTDs into this framework…
http://www.sabin.org/updates/pressreleases/new-framework-neglected-tropical-diseases-could-unlock-potential-world%E2%80%99s

Republic of Korea to double contribution to Global Fund over next three years

The Global Fund “welcomed an announcement by the Republic of Korea to double its contribution to the Global Fund over the next three years by drawing on the proceeds of a levy on airline tickets.” The Korean Ministry of Health will contribute US$6 million to the Global Fund for 2014-16. An additional US $10 million, from a levy on all passengers leaving Korea on international flights, will be paid by the Korean Ministry of Foreign Affairs to the Global Fund in five annual installments of $2 million from 2013-17. The 1,000 won (US $0.95) levy, known as the Global Poverty Eradication Tax, was introduced in 2007, primarily to contribute financial resources to fight poverty and disease in impoverished countries. Korea has contributed US$19 million since it started lending financial support to the Global Fund in 2004, of which US$6 million was pledged for the 2011-13 period.
http://www.theglobalfund.org/en/mediacenter/newsreleases/2013-11-21_Republic_of_Korea_Boosts_Contribution_to_Global_Fund/

IVI names three new Trustees

   The International Vaccine Institute (IVI) announced that Professor Fred Binka, Dr. Joseph J. Kim, and Dr. George R. Siber will join the IVI Board of Trustees. The three new Board members, who hail from Ghana, the United States, and Canada, respectively, will serve a three-year term to oversee the governance and management of the institute. IVI Director General Dr. Christian Loucq commented, “The new members bring scientific, industrial, and global health expertise that will boost IVI’s ability to make an impact in improving the health of the most impoverished. IVI has undergone several changes to strengthen its governance and management and to increase transparency. We look forward to capitalizing on the experience and knowledge they bring as we continue to evolve as an institute.”

Full media release: SEOUL, South Korea, Nov. 18, 2013 /PRNewswire:   http://www.prnewswire.com/news-releases/international-vaccine-institute-announces-appointments-of-new-members-to-its-board-of-trustees-232427031.html

Aeras elects Lota S. Zoth, CPA as Chair, Board of Directors

Aeras announced that Lota S. Zoth, CPA was appointed Chair of its Board of Directors, noting that Ms. Zoth “assumes leadership of Aeras during its 10th year, at a time when the organization is focused on diversifying and advancing a pipeline of next-generation vaccine candidates.” Ms. Zoth joined the board in 2011 and is a strategic finance and operations executive who served as Senior Vice President and Chief Financial Officer of MedImmune, Inc., now part of AstraZeneca. She replaces R. Gordon Douglas, Jr., outgoing Chair of the Board and Emeritus Professor of Medicine at Weill Cornell Medical College. Dr. Douglas served as Board Chair for the past 12 years and “guided the organization through its growth from a small nonprofit research group to an international nonprofit biotech with offices in South Africa and China; six TB vaccine candidates in its clinical portfolio; and global partnerships in Africa, Asia, Australia, Europe, and North America.”
November 21, 2013, ROCKVILLE, MD – http://www.aeras.org/pressreleases/aeras-announces-new-board-leadership#.UpEwd-Ky-F8

Gates Foundation announces winners in Grand Challenges Explorations (GCE) [Nov 2013]

    The Gates Foundation announced a new round of winners as part of its Grand Challenges Explorations (GCE) initiative. GCE grants associated with vaccines included those in the category: The ‘One Health’ Concept: Bringing Together Human and Animal Health for New Solutions – “Over the last century, both human and veterinary medicine have made great advancements. In spite of the many overlaps between the two disciplines, they have become distinctly separate, limiting cross-disciplinary sharing of knowledge. These projects are exploring innovative ideas within the concept of ‘One Health’ to address human and livestock diseases, human nutrition, health service delivery, and measurement of impact. Projects include:
:: Milosz Faber of Thomas Jefferson University in the U.S. will develop a rabies vaccine that both protects dogs against rabies and reduces their population levels to control the incidence of human rabies. Human rabies causes 70,000 deaths annually and is mostly spread by dogs.
:: George Warimwe of the Jenner Institute at the University of Oxford in the United Kingdom will develop a vaccine to protect a variety of species, including humans, sheep, and cattle, against Rift Valley fever, which can cause serious illness….”
Full media release: http://www.gatesfoundation.org/Media-Center/Press-Releases/2013/11/Gates-Foundation-Awards-Grants-to-Test-Ideas-2

PATH said it will receive two US$1 million grants from the Bill & Melinda Gates Foundation’s Grand Challenges Explorations initiative “to advance a new category of cold chain equipment and expand access to donated breast milk by simplifying human milk banking.” The two-year, follow-on grants recognize successful projects with additional funding, allowing PATH and collaborators to build on work already under way. The first grant will support PATH work with equipment manufacturers to design novel approaches that catalyze the introduction of low-cost, durable, freeze-safe cold chain solutions into country immunization programs. PATH aims to advance “fail-safe” innovations in cold boxes and vaccine carriers that allow vaccines to remain cold for longer periods of time without damaging freeze-sensitive vaccines. PATH will work with manufacturing partners to overcome technical hurdles through design optimization, laboratory testing, and field evaluations in country immunization supply chains. In addition, PATH will engage with key stakeholders and country decision-makers to raise awareness of the need to prevent vaccine freezing and assess demand for cold chain equipment that meets this need.
Full media release: http://www.path.org/news/press-room/660/

DFID – GAVI – Summary Assessment 2013

DFID –  GAVI – Summary Assessment 2013
Excerpt
Summary assessment: Continues to deliver results with activity across all reform priorities. Impact of increased focus on market shaping being felt. Key changes have begun to support health system strengthening.

Baseline
The GAVI Alliance is a public-private partnership committed to saving children’s lives and protecting people’s health by increasing access to immunisation in developing countries. The MAR highlighted several strengths:
:: GAVI has made a significant contribution to MDG 4 by increasing finance for vaccinations, including from innovative sources, and has improved coverage of new and underused vaccines.
:: It has a strong partnership with governments, civil society and the private sector.
:: It provides highly cost-effective health interventions with vaccines selected on strict criteria for health impact and cost effectiveness with appropriate administration costs.
:: It has effective financial oversight, with a proactive Audit and Finance Committee, an internal auditor and a robust Transparency and Accountability Policy.

The MAR also highlighted several weaknesses:
:: The need for more focus on market shaping to reduce prices and secure sustainable supply.
:: It has relatively poor performance of cash based programmes, particularly Health Systems Strengthening (HSS) support.
:: The need for a more systematic evidence based approach to working in fragile contexts.
:: There is lack of clarity in roles and responsibilities of key partners, such as WHO and UNICEF, and on the inclusion of civil society.

DFID’s reform priorities for the MAR Update were:
:: Better approach to working in fragile settings through the development of a policy and systematic evidence of performance in fragile contexts – assessed under attention to cross-cutting issues (fragile states).
:: Greater focus on outcomes and performance, specifically in relation to the delivery of its cash based programmes (HSS) – assessed under strategic and performance management and financial resource management.
:: Stronger performance on influencing markets and more strategic approach to procurement for sustainable and affordable vaccine supply – assessed under cost and value consciousness.
:: Further alignment and clarity in roles and responsibilities of partners, including civil society – assessed under partnership behaviour.

Summary of Overall Progress
GAVI continues to be a high performing institution providing a very cost-effective health intervention. From the 2011 MAR high baseline, evidence collected for the 2013 MAR Update demonstrates GAVI’s on-going commitment to improvement across the DFID reform priorities and in all at least some evidence of commitment being translated into implementation exists. However work streams are at different stages and for some, e.g. HSS support, it is too early to judge country level impact.

Full DFID Documentation – Multilateral Aid Review: Global Alliance for Vaccines and Immunisation (GAVI) at: https://www.gov.uk/government/publications/multilateral-aid-review-global-alliance-for-vaccines-and-immunisation-gavi

Comparison of the Use of H1N1 and seasonal influenza vaccinations between veterans and non-veterans in the United States, 2010

BMC Public Health
(Accessed 23 November 2013)
http://www.biomedcentral.com/bmcpublichealth/content

Research article
Comparison of the Use of H1N1 and seasonal influenza vaccinations between veterans and non-veterans in the United States, 2010
Claudia Der-Martirosian, Kevin C Heslin, Michael N Mitchell, Karen Chu, Kim Tran and Aram Dobalian
BMC Public Health 2013, 13:1082  doi:10.1186/1471-2458-13-1082
Published: 20 November 2013

Abstract (provisional)
Background
Veterans of the U.S. armed forces tend to be older and have more chronic health problems than the general adult population, which may place them at greater risk of complications from influenza. Despite Centers for Disease Control and Prevention (CDC) recommendations, seasonal influenza vaccination rates for the general adult population remain well below the national goal of 80%. Achieving this goal would be facilitated by a clearer understanding of which factors influence vaccination.

Methods
Using the 2010 U.S. National Health Interview Survey (NHIS), this study estimates models of two types of vaccinations (H1N1 and seasonal flu), assesses if the correlates differ for these vaccinations, and analyses the distribution of the correlates by veteran status.

Results
Veterans, women, non-Hispanic whites, non-smokers, those at high risk, educated, with health insurance, and who use clinics as a usual source of care were more likely to receive both types of vaccinations. Those who were older, married, and with higher income were more likely to get vaccinated for seasonal flu, but not for H1N1. Age and number of children living in the household were found to have different effects for H1N1 compared to seasonal flu.

Conclusion
Veterans are more likely to get vaccinated for seasonal influenza and H1N1 compared to the general population. This might be due to Veterans having better access to care or Veterans participating in better health care practices. Future studies should examine potential differences in flu vaccination use among Veterans using Veterans Affairs (VA) health care system vs. non-VA users.

Review of Institute of Medicine and National Research Council Recommendations for One Health Initiative

Emerging Infectious Diseases
Volume 19, Number 12—December 2013
http://www.cdc.gov/ncidod/EID/index.htm

Perspective
Review of Institute of Medicine and National Research Council Recommendations for One Health Initiative
Carol Rubin , Tanya Myers, William Stokes, Bernadette Dunham, Stic Harris, Beth Lautner, and Joseph Annelli
http://wwwnc.cdc.gov/eid/article/19/12/12-1659_article.htm

Abstract
Human health is inextricably linked to the health of animals and the viability of ecosystems; this is a concept commonly known as One Health. Over the last 2 decades, the Institute of Medicine (IOM) and the National Research Council (NRC) have published consensus reports and workshop summaries addressing a variety of threats to animal, human, and ecosystem health. We reviewed a selection of these publications and identified recommendations from NRC and IOM/NRC consensus reports and from opinions expressed in workshop summaries that are relevant to implementation of the One Health paradigm shift. We grouped these recommendations and opinions into thematic categories to determine if sufficient attention has been given to various aspects of One Health. We conclude that although One Health themes have been included throughout numerous IOM and NRC publications, identified gaps remain that may warrant targeted studies related to the One Health approach.

A mathematical model to predict the risk of hepatitis B infection through needle/syringe sharing in mass vaccination

Infectious Diseases of Poverty
http://www.idpjournal.com/content
[Accessed 23 November 2013]

Research Article
A mathematical model to predict the risk of hepatitis B infection through needle/syringe sharing in mass vaccination
Etsuji Okamoto
Infectious Diseases of Poverty 2013, 2:28  doi:10.1186/2049-9957-2-28
Published: 19 November 2013
http://www.idpjournal.com/content/2/1/28/abstract

Abstract (provisional)
Background
The Japanese Government settled a class litigation case with hepatitis B virus (HBV) carriers who claim to have been infected through needle/syringe sharing in mass vaccination with a blanket compensation agreement. However, it is difficult to estimate how many of the present HBV carriers were infected horizontally from mass vaccination and how many were infected vertically from mothers.

Methods
A mathematical model to predict the risk of infection through needle/syringe sharing in mass vaccination was proposed and a formula was developed. The formula was presented in a logarithmic graph enabling users to estimate how many people will be infected if a needle/syringe is shared by how many people for how many times under certain probability of infection. The formula was then applied to the historical data of mass tuberculin skin tests (TSTs) and BCG inoculation, from which a best estimate of how much needle/syringe sharing was practiced in different birth cohorts was determined.

Results
For the oldest cohort born between 1951 and 1955, the prevalence of HBV carriers—0.65% at birth through vertical transmission—more than doubled in 1995 (1.46% ) through horizontal transmission. If the probability of infection through needle/syringe sharing is assumed to be 10% , it is theoretically likely that an average of five or more people shared a needle/syringe four times to achieve the prevalence of HBV carriers in 1995. However, for the youngest cohort born between 1981 and 1985, the effects of needle/syringe sharing were negligible because the later prevalence of HBV carriers was lower than the prevalence at birth.

Conclusions
More than half of the HBV carriers born in the early 1950s might have contracted the disease by mass vaccinations. Japan’s experience needs to be shared with other countries as a caution in conducting mass vaccination programs under scarce needle/syringe supply.

Potential Impact of the US President’s Emergency Plan for AIDS Relief on the Tuberculosis/HIV Coepidemic in Selected Sub-Saharan African Countries

Journal of Infectious Diseases
Volume 208 Issue 12 December 15, 2013
http://jid.oxfordjournals.org/content/current

Potential Impact of the US President’s Emergency Plan for AIDS Relief on the Tuberculosis/HIV Coepidemic in Selected Sub-Saharan African Countries
Viviane D. Lima1,2, Reuben Granich3, Peter Phillips1,4, Brian Williams5 and Julio S. G. Montaner1,2
http://jid.oxfordjournals.org/content/208/12/2075.abstract

Abstract
Background. There are limited data measuring the impact of expanded human immunodeficiency virus (HIV) prevention activities on the tuberculosis epidemic at the country level. Here, we characterized the potential impact of the US President’s Emergency Plan for AIDS Relief (PEPFAR) on the tuberculosis epidemic in sub-Saharan Africa.

Methods. We selected 12 focus countries (countries receiving the greatest US government investments) and 29 nonfocus countries (controls). We used tuberculosis incidence and mortality rates and relative risks to compare time periods before and after PEPFAR’s inception, and a tuberculosis/HIV indicator to calculate the rate of change in tuberculosis incidence relative to the HIV prevalence.

Results. Comparing the periods before and after PEPFAR’s implementation, both tuberculosis incidence and mortality rates have diminished significantly and to a higher degree in focus countries. The relative risk for developing tuberculosis, comparing those with and without HIV, was 22.5 for control and 20.0 for focus countries. In most focus countries, the tuberculosis epidemic is slowing down despite some regions still experiencing an increase in HIV prevalence.

Conclusions. This ecological study showed that PEPFAR had a more consistent and substantial effect on HIV and tuberculosis in focus countries, highlighting the likely link between high levels of HIV investment and broader effects on related diseases such as tuberculosis.

Lancet Series – Bangladesh: Innovation for Universal Health Coverage

The Lancet  
Nov 23, 2013  Volume 382  Number 9906  p1679 – 1756  e25
http://www.thelancet.com/journals/lancet/issue/current

Series
Bangladesh: Innovation for Universal Health Coverage
The Bangladesh paradox: exceptional health achievement despite economic poverty
A Mushtaque R Chowdhury, Abbas Bhuiya, Mahbub Elahi Chowdhury, Sabrina Rasheed, Zakir Hussain, Lincoln C Chen
Preview |
Bangladesh, the eighth most populous country in the world with about 153 million people, has recently been applauded as an exceptional health performer. In the first paper in this Series, we present evidence to show that Bangladesh has achieved substantial health advances, but the country’s success cannot be captured simplistically because health in Bangladesh has the paradox of steep and sustained reductions in birth rate and mortality alongside continued burdens of morbidity. Exceptional performance might be attributed to a pluralistic health system that has many stakeholders pursuing women-centred, gender-equity-oriented, highly focused health programmes in family planning, immunisation, oral rehydration therapy, maternal and child health, tuberculosis, vitamin A supplementation, and other activities, through the work of widely deployed community health workers reaching all households.

Bangladesh: Innovation for Universal Health Coverage
Harnessing pluralism for better health in Bangladesh
Syed Masud Ahmed, Timothy G Evans, Hilary Standing, Simeen Mahmud
Preview |
How do we explain the paradox that Bangladesh has made remarkable progress in health and human development, yet its achievements have taken place within a health system that is frequently characterised as weak, in terms of inadequate physical and human infrastructure and logistics, and low performing? We argue that the development of a highly pluralistic health system environment, defined by the participation of a multiplicity of different stakeholders and agents and by ad hoc, diffused forms of management has contributed to these outcomes by creating conditions for rapid change.

5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial

The Lancet Infectious Diseases
Dec 2013  Volume 13  Number 12  p995 – 1098
http://www.thelancet.com/journals/laninf/issue/current

A rare success for cholera vaccines
Saranya Sridhar a, Narendra Kumar Arora b
http://www.thelancet.com/journals/laninf/article/PIIS1473-3099%2813%2970296-2/fulltext?_eventId=login

Cholera is a truly neglected infectious disease that is endemic in most parts of Africa and Asia. Despite an estimated annual burden of 2–4 million cases,1 it garners public attention only when outbreaks rampage through disaster-struck populations.2 Control of cholera depends on the long-term strategy of improving water quality and sanitation systems, but an effective vaccine conferring durable protection could offer an additional weapon in the depleted armoury of prevention strategies for this disease.

In 2001, WHO prequalified the licensed oral cholera vaccine Dukoral (SBL Vaccin AB, Sweden) for purchase by UN organisations.3 However, this vaccine is expensive, its efficacy lasts for only 2 years,4 and it is primarily used to protect travellers.3 In a technology transfer that should serve as a model for vaccine development, a modified version of the vaccine (Shanchol, Shantha Biotechnics, India) was manufactured and licensed in India in 2009. Shanchol was prequalified by the WHO in 2011. A field trial5 showed 67% cumulative efficacy in the first 2 years after vaccination. At that time, we sounded a note of cautious optimism and awaited the results of longer follow-up since other promising cholera vaccines with similar efficacy had failed to deliver longlasting protection.6

In The Lancet Infectious Diseases, Sujit Bhattacharya and colleagues7 report on whether Shanchol was protective over 5 years in a follow-up of 66 900 participants in a cluster-randomised placebo-controlled trial in Kolkata, India. The whole-cell vaccine containing killed strains from the O1 and O139 serogroups was given in two doses 2 weeks apart to non-pregnant individuals older than 1 year. The vaccine showed 65% (95% CI lower boundary of 52%) cumulative efficacy in the 5 year period for prevention of cholera episodes severe enough for individuals to seek treatment. This cholera vaccine is the first in the long history of cholera vaccine development to show more than 50% efficacy lasting up to 5 years. However, in children aged 1–5 years, who are at greatest risk of disease, the vaccine conferred only 42% cumulative efficacy (95% CI lower boundary of 5%) and too few cases occurred during the fifth year of follow-up to judge whether protection in these children lasted into the fifth year after vaccination. This lower level of protection is compounded by the difficulty of delivering oral vaccination to young children in poor sanitary and hygiene conditions. Nonetheless, we believe this result of an unprecedented level of long-term efficacy will be a giant leap forward for global control of cholera.

Despite this advance, questions remain. How do we improve vaccine efficacy in young children? The cholera community might learn from influenza vaccination, in which live attenuated vaccines are most efficacious in children and killed vaccines most efficacious in adults. Perhaps more effort needs to be placed on development, improvement, and testing of new and old attenuated cholera vaccines.8 A booster dose 2–3 years after the first vaccination might be necessary. Would the vaccine work equally well in areas that are not cholera endemic?      In endemic cholera areas, such as the Kolkata trial site,7 the vaccine might boost existing naturally acquired immunity. This boosting effect is given more credence by trial results showing an increased efficacy in the fourth and fifth year of the study, especially in adults, after a large cholera outbreak in the third year. Whether the vaccine will be equally efficacious in immunologically naive individuals, especially in the context of cholera outbreaks, is unknown.    Individuals with HIV infection and those who are pregnant and elderly are the other high-risk populations in whom this vaccine needs to be assessed.

Vaccine efficacy was shown only against the O1 strain circulating in the study population. Efficacy against the O139 strains and newly emergent O1 strains expressing the classical toxins should be investigated.3 Resolution of whether the vaccine can reduce infection or transmission and not just protect against severe disease would help to further strengthen the case for vaccination.

We are only allowed the luxury of posing such questions because today’s study offers the cholera community an effective vaccine conferring durable protection. Despite all these unresolved issues, the need for an affordable cholera vaccine for international use has now been partly fulfilled. The focus now shifts to global policy makers and individual governments as they determine how to translate these study results into effective public good. While we celebrate a rare success story, perhaps the first in the WHO supported Decade of Vaccines collaboration, we need to seize this opportunity to transform global cholera control before we are once again overwhelmed by the next, inevitable, outbreak.

   References
1 M Ali, AL Lopez, YA You et al.
The global burden of cholera
Bull World Health Organ, 90 (2012), pp. 209–218A
2 Update: outbreak of cholera—Haiti, 2010
MMWR Morb Mortal Wkly Rep, 59 (2010), pp. 1586–1590
3 WHO Cholera, 2012
Wkly Epidemiol Rec, 88 (2013), pp. 321–334
4 FP Van Loon, JD Clemens, J Chakraborty et al.
Field trial of inactivated oral cholera vaccines in Bangladesh: results from 5 years of follow-up
Vaccine, 14 (1996), pp. 162–166
5  D Sur, AL Lopez, S Kanungo et al.
Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial
Lancet, 374 (2009), pp. 1694–1702
6 S Sridhar
An affordable cholera vaccine: an important step forward
Lancet, 374 (2009), pp. 1658–1660
7 SK Bhattacharya, D Sur, M Ali et al.
5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial
Lancet Infect Dis (2013) published online Oct 18. http://dx.doi.org.ezproxy.med.nyu.edu/10.1016/S1473-3099(13)70273-1
8  M Pastor, JL Pedraz, A Esquisabel
The state-of-the-art of approved and under-development cholera vaccines
Vaccine, 31 (2013), pp. 4069–4078

5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial
Sujit K Bhattacharya MD a b, Dipika Sur MD a, Dr Mohammad Ali PhD c, Suman Kanungo DIH a, Young Ae You MS c, Byomkesh Manna PhD a, Binod Sah MBBS c, Swapan K Niyogi MD a, Jin Kyung Park PhD c, Banwarilal Sarkar PhD a, Mahesh K Puri MSc c, Deok Ryun Kim MS c, Jacqueline L Deen MD d, Jan Holmgren PhD e, Rodney Carbis BSc c, Mandeep Singh Dhingra MD f, Allan Donner PhD g, G Balakrish Nair PhD a, Anna Lena Lopez MD c h, Thomas F Wierzba PhD c, John D Clemens MD c i j
http://www.thelancet.com/journals/laninf/article/PIIS1473-3099%2813%2970273-1/abstract
Summary
Background
Efficacy and safety of a two-dose regimen of bivalent killed whole-cell oral cholera vaccine (Shantha Biotechnics, Hyderabad, India) to 3 years is established, but long-term efficacy is not. We aimed to assess protective efficacy up to 5 years in a slum area of Kolkata, India.

Methods
In our double-blind, cluster-randomised, placebo-controlled trial, we assessed incidence of cholera in non-pregnant individuals older than 1 year residing in 3,933 dwellings (clusters) in Kolkata, India. We randomly allocated participants, by dwelling, to receive two oral doses of modified killed bivalent whole-cell cholera vaccine or heat-killed Escherichia coli K12 placebo, 14 days apart. Randomisation was done by use of a computer-generated sequence in blocks of four. The primary endpoint was prevention of episodes of culture-confirmed Vibrio cholerae O1 diarrhoea severe enough for patients to seek treatment in a health-care facility. We identified culture-confirmed cholera cases among participants seeking treatment for diarrhoea at a study clinic or government hospital between 14 days and 1,825 days after receipt of the second dose. We assessed vaccine protection in a per-protocol population of participants who had completely ingested two doses of assigned study treatment.

Findings
69 of 31,932 recipients of vaccine and 219 of 34,968 recipients of placebo developed cholera during 5 year follow-up (incidence 2.2 per 1000 in the vaccine group and 6.3 per 1000 in the placebo group). Cumulative protective efficacy of the vaccine at 5 years was 65% (95% CI 52-74; p<0·0001), and point estimates by year of follow-up suggested no evidence of decline in protective efficacy.

Interpretation
Sustained protection for 5 years at the level we reported has not been noted previously with other oral cholera vaccines. Established long-term efficacy of this vaccine could assist policy makers formulate rational vaccination strategies to reduce overall cholera burden in endemic settings.

Funding
Bill & Melinda Gates Foundation and the governments of South Korea and Sweden.

Identification and Control of a Poliomyelitis Outbreak in Xinjiang, China

New England Journal of Medicine
November 21, 2013  Vol. 369 No. 21
http://www.nejm.org/toc/nejm/medical-journal

Original Article
Identification and Control of a Poliomyelitis Outbreak in Xinjiang, China
Hui-Ming Luo, M.D., Yong Zhang, M.D., Ph.D., Xin-Qi Wang, M.D., Wen-Zhou Yu, M.D., Ph.D., M.P.H., Ning Wen, M.Sc., Dong-Mei Yan, M.Sc., Hua-Qing Wang, M.D., Ph.D., Fuerhati Wushouer, M.D., Hai-Bo Wang, M.D., Ph.D., Ai-Qiang Xu, M.D., Jing-Shan Zheng, M.D., De-Xin Li, M.D., Hui Cui, B.Sc., Jian-Ping Wang, M.Sc., Shuang-Li Zhu, B.Sc., Zi-Jian Feng, M.D., Fu-Qiang Cui, M.D., Ph.D., M.P.H., Jing Ning, B.Sc., Li-Xin Hao, M.D., Ph.D., Chun-Xiang Fan, M.Sc., Gui-Jun Ning, M.Sc., Hong-Jie Yu, M.D., Shi-Wen Wang, M.D., Ph.D., Da-Wei Liu, M.D., Dong-Yan Wang, B.Sc., Jian-Ping Fu, M.D., Ai-li Gou, B.Sc., Guo-Min Zhang, Ph.D., Guo-Hong Huang, B.Sc., Yuan-Sheng Chen, M.D., Ph.D., Sha-Sha Mi, M.D., Yan-Min Liu, M.D., Da-Peng Yin, Ph.D., Hui Zhu, B.Sc., Xin-Chun Fan, B.Sc., Xin-Lan Li, B.Sc., Yi-Xin Ji, M.Sc., Ke-Li Li, M.D., Hai-Shu Tang, M.Sc., Wen-Bo Xu, M.D., Yu Wang, M.D., Ph.D., M.P.H, and Wei-Zhong Yang, M.D.
N Engl J Med 2013; 369:1981-1990November 21, 2013DOI: 10.1056/NEJMoa1303368

Background
The last case of infection with wild-type poliovirus indigenous to China was reported in 1994, and China was certified as a poliomyelitis-free region in 2000. In 2011, an outbreak of infection with imported wild-type poliovirus occurred in the province of Xinjiang.
Full Text of Background…

Methods
We conducted an investigation to guide the response to the outbreak, performed sequence analysis of the poliovirus type 1 capsid protein VP1 to determine the source, and carried out serologic and coverage surveys to assess the risk of viral propagation. Surveillance for acute flaccid paralysis was intensified to enhance case ascertainment.
Full Text of Methods…

Results
Between July 3 and October 9, 2011, investigators identified 21 cases of infection with wild-type poliovirus and 23 clinically compatible cases in southern Xinjiang. Wild-type poliovirus type 1 was isolated from 14 of 673 contacts of patients with acute flaccid paralysis (2.1%) and from 13 of 491 healthy persons who were not in contact with affected persons (2.6%). Sequence analysis implicated an imported wild-type poliovirus that originated in Pakistan as the cause of the outbreak. A public health emergency was declared in Xinjiang after the outbreak was confirmed. Surveillance for acute flaccid paralysis was enhanced, with daily reporting from all public and private hospitals. Five rounds of vaccination with live, attenuated oral poliovirus vaccine (OPV) were conducted among children and adults, and 43 million doses of OPV were administered. Trivalent OPV was used in three rounds, and monovalent OPV type 1 was used in two rounds. The outbreak was stopped 1.5 months after laboratory confirmation of the index case.
Full Text of Results…

Conclusions
The 2011 outbreak in China showed that poliomyelitis-free countries remain at risk for outbreaks while the poliovirus circulates anywhere in the world. Global eradication of poliomyelitis will benefit all countries, even those that are currently free of poliomyelitis.

Editorial: No Country Is Safe without Global Eradication of Poliomyelitis

New England Journal of Medicine
November 21, 2013  Vol. 369 No. 21
http://www.nejm.org/toc/nejm/medical-journal

Editorial
No Country Is Safe without Global Eradication of Poliomyelitis
Trevor Mundel, M.D., Ph.D., and Walter A. Orenstein, M.D.
N Engl J Med 2013; 369:2045-2046November 21, 2013DOI: 10.1056/NEJMe131159
http://www.nejm.org/doi/full/10.1056/NEJMe1311591

In 1988, the World Health Assembly endorsed the goal of eradicating poliomyelitis worldwide. At the time, the estimated annual number of new cases of paralysis was 350,000, and poliomyelitis was considered to be endemic in 125 countries.1 In the 25 years since then, the incidence of poliomyelitis has been reduced by more than 99%, and only three countries — Pakistan, Nigeria, and Afghanistan — have never terminated indigenous transmission.1,2

Wild-type poliovirus type 2 has probably been eradicated; the last naturally occurring case was detected in 1999.2 Wild-type poliovirus type 3 appears to be close to eradication, with no new cases detected in 2013 (as of October 31, 2013).3-5 However, wild-type poliovirus type 1 remains in circulation.2,3 As illustrated by the 2011 poliomyelitis outbreak in China — a country that had not reported a case of paralysis caused by wild-type polioviruses since 1994 — as long as polioviruses circulate anywhere in the world, they can be exported to countries that are now poliomyelitis-free and can cause serious outbreaks.6

Public health authorities in China are to be commended for containing the outbreak so quickly. As described by Luo et al.6 in this issue of the Journal, a mass campaign to inoculate children with trivalent oral poliovirus vaccine was started within 3 weeks of outbreak confirmation, and the last case was detected approximately 1 month after the campaign was initiated. However, to make sure that polioviruses were truly eliminated, a total of five mass campaigns were conducted, in which 43.7 million doses of oral poliovirus vaccine were administered.6

The cost of containing the outbreak was considerable. Approximately $26 million (in U.S. dollars) was allocated for outbreak control. This cost does not include the less tangible cost of diverting hundreds of public health experts and local health workers from other important public health work. The apparently high immunity levels in this area of China probably made containment easier, since the population immunity was already close to herd-immunity thresholds.6

Should a similar outbreak occur in a poorer country with lower routine immunization coverage, or in a country that is not capable of responding as quickly, containment could prove far more difficult, as may be the case in the current importation of the poliovirus to the Horn of Africa and the Middle East, including Syria. Underscoring the highly infectious nature of poliomyelitis, importation of polioviruses from reservoir countries into areas that had been free of wild-type poliovirus has occurred in at least six countries so far this year, including Somalia (which had been free of the wild-type poliovirus since 2007), Kenya, Ethiopia, Syria, Cameroon, and Israel.3,7 The outbreak in the Horn of Africa was genetically traced to viruses from Nigeria, whereas the widespread circulation of wild-type poliovirus type 1 in Israel was linked to virus originating in Pakistan.7,8

To end poliomyelitis forever, the Global Polio Eradication Initiative (GPEI) has developed a comprehensive strategic plan to interrupt all transmission of wild-type poliovirus by the end of 2014 and to certify the world as poliomyelitis-free by 2018.2 Global eradication will require several key actions; these include administering oral poliovirus vaccine to interrupt the transmission of wild-type polioviruses, building and sustaining political commitment, improving routine immunization delivery in remaining reservoir countries, delivering vaccines to children living in areas in conflict, and providing rigorous, ongoing oversight.

One essential part of the plan was to replace the current trivalent oral poliovirus vaccine with a bivalent vaccine containing only virus types 1 and 3. Oral poliovirus vaccine has been the major vaccine used in the eradication program because it is easy to administer, can passively immunize persons who do receive the vaccine directly, is relatively inexpensive, and induces greater intestinal immunity than that conferred by inactivated poliovirus vaccine. This superior intestinal immunity should be more effective in decreasing transmission, since in the developing world most poliovirus is thought to be spread by the fecal–oral route. However, on rare occasions, oral poliovirus vaccine has been known to cause paralysis, either as a result of vaccine-associated paralytic polio or by means of circulating vaccine-derived polioviruses that have acquired some properties of wild viruses.3,9 Removing type 2 oral poliovirus vaccine should reduce vaccine-associated paralytic polio and cases of circulating vaccine-derived poliovirus infection by about 40% and more than 95%, respectively.3,9

A further benefit of the bivalent oral poliovirus vaccine (as compared with the trivalent vaccine) is that it would enhance immunogenicity against types 1 and 3 poliovirus.10 To maintain population immunity to the type 2 virus and to reduce the risk of outbreaks of type 2 if it were reintroduced (e.g., through a break in laboratory containment), the administration of at least one dose of inactivated poliovirus is recommended in routine immunization.11

The estimated cost of the 2013–2018 GPEI strategic plan is approximately $5.5 billion.2 This is clearly a substantial investment, but the failure to achieve global eradication would cost far more. Mathematical models suggest that abandoning the program before eradication is achieved would result in a massive resurgence of poliomyelitis, with approximately 200,000 cases of paralysis annually.12 In addition to the huge financial burden this would impose — particularly in countries in the developing world — the human costs of a resurgence of poliomyelitis are incalculable.

The history of successful eradication efforts over more than two decades has proven that we can finish the job. The real lesson of the outbreak in China is that if we do not, any country is vulnerable to reimportation of poliomyelitis. Without question, the best defense against poliovirus is a good offense that eliminates the virus from the remaining reservoirs and truly eradicates the disease.

Vaccine-Preventable Disease Among Homeschooled Children: Two Cases of Tetanus in Oklahoma

Pediatrics
November 2013, VOLUME 132 / ISSUE 5
http://pediatrics.aappublications.org/current.shtml
[Reviewed earlier]

Online
Case Report
Vaccine-Preventable Disease Among Homeschooled Children: Two Cases of Tetanus in Oklahoma
Matthew G. Johnson, MDa, Kristy K. Bradley, DVMb, Susan Mendus, MPHc, Laurence Burnsed, MPHd, Rachel Clinton, MSd, and Tejpratap Tiwari, MDe

Abstract
Homeschooled children represent an increasing proportion of school-aged children in the United States. Immunization rates among homeschooled children are largely unknown because they are usually not subject to state-based school-entry vaccination requirements. Geographic foci of underimmunized children can increase the risk for outbreaks of vaccine-preventable diseases. In 2012, 2 cases of tetanus were reported in Oklahoma; both cases involved homeschooled children without documentation of diphtheria-tetanus-acellular pertussis vaccination. We describe the characteristics of both patients and outline innovative outreach measures with the potential to increase vaccination access and coverage among homeschooled children.

Characterization of Regional Influenza Seasonality Patterns in China and Implications for Vaccination Strategies: Spatio-Temporal Modeling of Surveillance Data

PLoS Medicine
(Accessed 23 November 2013)
http://www.plosmedicine.org/

Research Article
Characterization of Regional Influenza Seasonality Patterns in China and Implications for Vaccination Strategies: Spatio-Temporal Modeling of Surveillance Data
Hongjie Yu, Wladimir J. Alonso, Luzhao Feng, Yi Tan, Yuelong Shu, Weizhong Yang, Cécile Viboud
http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.1001552
Abstract
Background
The complexity of influenza seasonal patterns in the inter-tropical zone impedes the establishment of effective routine immunization programs. China is a climatologically and economically diverse country, which has yet to establish a national influenza vaccination program. Here we characterize the diversity of influenza seasonality in China and make recommendations to guide future vaccination programs.

Methods and Findings
We compiled weekly reports of laboratory-confirmed influenza A and B infections from sentinel hospitals in cities representing 30 Chinese provinces, 2005–2011, and data on population demographics, mobility patterns, socio-economic, and climate factors. We applied linear regression models with harmonic terms to estimate influenza seasonal characteristics, including the amplitude of annual and semi-annual periodicities, their ratio, and peak timing. Hierarchical Bayesian modeling and hierarchical clustering were used to identify predictors of influenza seasonal characteristics and define epidemiologically-relevant regions. The annual periodicity of influenza A epidemics increased with latitude (mean amplitude of annual cycle standardized by mean incidence, 140% [95% CI 128%-151%] in the north versus 37% [95% CI 27%-47%] in the south, p<0.0001). Epidemics peaked in January–February in Northern China (latitude ≥33°N) and April–June in southernmost regions (latitude <27°N). Provinces at intermediate latitudes experienced dominant semi-annual influenza A periodicity with peaks in January–February and June–August (periodicity ratio >0.6 in provinces located within 27.4°N-31.3°N, slope of latitudinal gradient with latitude -0.016 [95% CI -0.025 to -0.008], p<0.001). In contrast, influenza B activity predominated in colder months throughout most of China. Climate factors were the strongest predictors of influenza seasonality, including minimum temperature, hours of sunshine, and maximum rainfall. Our main study limitations include a short surveillance period and sparse influenza sampling in some of the southern provinces.

Conclusions
Regional-specific influenza vaccination strategies would be optimal in China; in particular, annual campaigns should be initiated 4–6 months apart in Northern and Southern China. Influenza surveillance should be strengthened in mid-latitude provinces, given the complexity of seasonal patterns in this region. More broadly, our findings are consistent with the role of climatic factors on influenza transmission dynamics.

Editors’ Summary
Background
Every year, millions of people worldwide catch influenza, a viral disease of the airways. Most infected individuals recover quickly but seasonal influenza outbreaks (epidemics) kill about half a million people annually. These epidemics occur because antigenic drift—frequent small changes in the viral proteins to which the immune system responds—means that an immune response produced one year provides only partial protection against influenza the next year. Annual vaccination with a mixture of killed influenza viruses of the major circulating strains boosts this natural immunity and greatly reduces the risk of catching influenza. Consequently, many countries run seasonal influenza vaccination programs. Because the immune response induced by vaccination decays within 4–8 months of vaccination and because of antigenic drift, it is important that these programs are initiated only a few weeks before the onset of local influenza activity. Thus, vaccination starts in early autumn in temperate zones (regions of the world that have a mild climate, part way between a tropical and a polar climate), because seasonal influenza outbreaks occur in the winter months when low humidity and low temperatures favor the transmission of the influenza virus.

Why Was This Study Done?
Unlike temperate regions, seasonal influenza patterns are very diverse in tropical countries, which lie between latitudes 23.5°N and 23.5°S, and in the subtropical countries slightly north and south of these latitudes. In some of these countries, there is year-round influenza activity, in others influenza epidemics occur annually or semi-annually (twice yearly). This complexity, which is perhaps driven by rainfall fluctuations, complicates the establishment of effective routine immunization programs in tropical and subtropical countries. Take China as an example. Before a national influenza vaccination program can be established in this large, climatologically diverse country, public-health experts need a clear picture of influenza seasonality across the country. Here, the researchers use spatio-temporal modeling of influenza surveillance data to characterize the seasonality of influenza A and B (the two types of influenza that usually cause epidemics) in China, to assess the role of putative drivers of seasonality, and to identify broad epidemiological regions (areas with specific patterns of disease) that could be used as a basis to optimize the timing of future Chinese vaccination programs.

What Did the Researchers Do and Find?
The researchers collected together the weekly reports of laboratory-confirmed influenza prepared by the Chinese national sentinel hospital-based surveillance network between 2005 and 2011, data on population size and density, mobility patterns, and socio-economic factors, and daily meteorological data for the cities participating in the surveillance network. They then used various statistical modeling approaches to estimate influenza seasonal characteristics, to assess predictors of influenza seasonal characteristics, and to identify epidemiologically relevant regions. These analyses indicate that, over the study period, northern provinces (latitudes greater than 33°N) experienced winter epidemics of influenza A in January–February, southern provinces (latitudes less than 27°N) experienced peak viral activity in the spring (April–June), and provinces at intermediate latitudes experienced semi-annual epidemic cycles with infection peaks in January–February and June–August. By contrast, influenza B activity predominated in the colder months throughout China. The researchers also report that minimum temperatures, hours of sunshine, and maximum rainfall were the strongest predictors of influenza seasonality.

What Do These Findings Mean?
These findings show that influenza seasonality in China varies between regions and between influenza virus types and suggest that, as in other settings, some of these variations might be associated with specific climatic factors. The accuracy of these findings is limited by the short surveillance period, by sparse surveillance data from some southern and mid-latitude provinces, and by some aspects of the modeling approach used in the study. Further surveillance studies need to be undertaken to confirm influenza seasonality patterns in China. Overall, these findings suggest that, to optimize routine influenza vaccination in China, it will be necessary to stagger the timing of vaccination over three broad geographical regions. More generally, given that there is growing interest in rolling out national influenza immunization programs in low- and middle-income countries, these findings highlight the importance of ensuring that vaccination strategies are optimized by taking into account local disease patterns.

.
Perspective
Complex Disease Dynamics and the Design of Influenza Vaccination Programs
Steven Riley
http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.1001553

For influenza vaccine programs to be optimal from the point of view of the individual at risk of infection, two conditions must be met. First, the vaccine must contain antigens that are well-matched to currently circulating strains [1]. Second, the vaccine must be administered at the right time: early enough that there is sufficient time for antibodies to rise in response to the vaccination, but not so early that protection by the vaccine wanes prior to infectious challenge [2]. The rate of waning of vaccine-induced protection against influenza is particularly high for older adults, one of the groups most at-risk of severe outcomes and often a top priority for national vaccination programs. Therefore, good knowledge of likely temporal trends in the risk of influenza infection is a necessary prerequisite for the design of optimal vaccination programs.

In this week’s PLOS Medicine, Cécile Viboud and colleagues [3] present an extensive analysis of sentinel virological surveillance of influenzas A(H3N2) and B from China with the objective of finding epidemiological patterns that support the design of the country’s first national influenza vaccination program. The authors use time series of viral isolation data from a network of sentinel hospitals, finding strong evidence for key epidemiological features of the incidence of influenza subtypes. Rather than relying on syndromic definitions or excess mortality, these biologically robust outcomes identify the patterns of circulating strains with high specificity.    Despite variability in both the propensity of individuals to seek treatment and the likelihood of them being tested, virological surveillance data accurately describe the timing of peak incidence, the duration of elevated incidence (the influenza season), and periods when influenza is absent (provided testing levels are high year-round).

In many temperate populations such as the United States, knowledge of epidemiological patterns of influenza incidence has facilitated the robust design of vaccination programs [4]: incidence is strongly seasonal, with a very low risk of infection during the summer. The vast majority of infections are focused in a 6–8 week period in the winter months. Therefore, vaccination programs that are expected to last ~6 weeks are initiated ~12 weeks prior to the expected start of the season (the beginning of October in the Northern Hemisphere and the beginning of April in the Southern Hemisphere).

At lower latitudes, patterns are far less clear [5]. Equatorial populations such as Singapore report almost constant year-round incidence of influenza-like illness [6], while some subtropical locations, such as Hong Kong, exhibit weak biennial cycles, with their seasonality characterized primarily by a clear off-season [7]. A study of influenza patterns in Brazil, a country with a large population spanning a wide range of latitudes, revealed wave-like dynamics originating in the less populated equatorial region and travelling out towards larger temperate populations (based on excess pneumonia and influenza mortality) [8].

In their study, Viboud and colleagues were able to separate China into three epidemiological zones for influenza A(H3N2). In the temperate north, incidence peaked sharply during January and February, while in the tropical south, a longer epidemic with a lower peak was observed during April and May. The regions in the middle latitudinal zone exhibited biannual cycles with smaller incidence peaks temporally aligned with their northern and the southern neighbors.

Intriguingly, there were clear differences in the spatial patterns of influenza B compared with those of influenza A. There was little evidence of biannual cycles for influenza B, with the timing of the single peak each year closely correlated with latitude: epidemics occurred first in the north and then progressed steadily to the south. Perhaps most striking, the authors also found that the proportion of samples positive for influenza B increased from less than 20% in the northernmost provinces to almost 50% in the southernmost provinces. These observations point to fundamentally different circulation patterns between influenzas A(H3N2) and B and should motivate systematic phylogeographical and serotype studies of influenza B at the national scale in China.

The observed differences in circulation patterns between influenzas A(H3N2) and B present challenges for the design of vaccination programs at middle and lower latitudes in China. As the authors observe, the timing of peaks in the southernmost provinces is only marginally ahead of Southern Hemisphere populations and suggests that those provinces may wish to follow the Southern Hemisphere timetable. However, such a decision might be slightly premature: genetic data from even a small subset of the viral isolates used for this study could give a definitive picture of the ancestral relationship between viruses circulating in southern China relative to viruses in northern China and Southern Hemisphere populations.

A lasting legacy of the 2009 pandemic is increased interest in novel methods of manufacture for influenza vaccines [9]. Although the vast majority of vaccines delivered today arise from egg-based production systems (not substantially different from those used for the first vaccine trials approx 70 years ago), there are a number of alternative production processes under investigation that may reduce both costs and timelines [10],[11],[12]. When these technologies are fully developed, they could greatly facilitate the redesign of vaccination programs for both seasonal and pandemic influenza. As epidemiological and phylogenetic studies reveal more about the circulation of specific influenza virus subtypes in different regions of the world, it seems likely that the current system of selecting only two official vaccine strain sets per year will be refined. The results presented by Viboud and colleagues [3] suggest that rapidly expanding vaccination programs in populous mid-latitude provinces of China may provide an ideal setting in which to investigate the possible benefits of rapid vaccine production and locally-informed strain selection.

NTDs V.2.0: “Blue Marble Health”—Neglected Tropical Disease Control and Elimination in a Shifting Health Policy Landsca

PLoS Neglected Tropical Diseases
November 2013
http://www.plosntds.org/article/browseIssue.action

Viewpoints
NTDs V.2.0: “Blue Marble Health”—Neglected Tropical Disease Control and Elimination in a Shifting Health Policy Landscape
Peter J. Hotez
Abstract
The concept of the neglected tropical diseases (NTDs) was established in the aftermath of the Millennium Development Goals. Here, we summarize the emergence of several new post-2010 global health documents and policies, and how they may alter the way we frame the world’s major NTDs since they were first highlighted. These documents include a new Global Burden of Disease 2010 Study that identifies visceral leishmaniasis and food-borne trematode infections as priority diseases beyond the seven NTDs originally targeted by preventive chemotherapy, a London Declaration for access to essential medicines, and a 2013 World Health Assembly resolution on NTDs. Additional information highlights an emerging dengue fever pandemic. New United Nations resolutions on women and the non-communicable diseases (NCDs) have not yet embraced NTDs, which may actually be the most common afflictions of girls and women and represent a stealth cause of NCDs. NTDs also have important direct and collateral effects on HIV/AIDS and malaria, and there is now a robust evidence base and rationale for incorporating NTDs into the Global Fund to Fight AIDS, Tuberculosis, and Malaria. “Blue marble health” is an added concept that recognizes a paradoxical NTD disease burden among the poor living in G20 (Group of Twenty) and other wealthy countries, requiring these nations to take greater ownership for both disease control and research and development. As we advance past the year 2015, it will be essential to incorporate global NTD elimination into newly proposed Sustainable Development Goals.

Cholera Vaccination Campaign Contributes to Improved Knowledge Regarding Cholera and Improved Practice Relevant to Waterborne Disease in Rural Hait

PLoS Neglected Tropical Diseases
November 2013
http://www.plosntds.org/article/browseIssue.action

Research Article
Cholera Vaccination Campaign Contributes to Improved Knowledge Regarding Cholera and Improved Practice Relevant to Waterborne Disease in Rural Haiti
Omowunmi Aibana, Molly Franke, Jessica Teng, Johanne Hilaire, Max Raymond, Louise C. Ivers

Background
Haiti’s cholera epidemic has been devastating partly due to underlying weak infrastructure and limited clean water and sanitation. A comprehensive approach to cholera control is crucial, yet some have argued that oral cholera vaccination (OCV) might result in reduced hygiene practice among recipients. We evaluated the impact of an OCV campaign on knowledge and health practice in rural Haiti.

Methodology/Principal Findings
We administered baseline surveys on knowledge and practice relevant to cholera and waterborne disease to every 10th household during a census in rural Haiti in February 2012 (N = 811). An OCV campaign occurred from May–June 2012 after which we administered identical surveys to 518 households randomly chosen from the same region in September 2012. We compared responses pre- and post-OCV campaign. Post-vaccination, there was improved knowledge with significant increase in percentage of respondents with ≥3 correct responses on cholera transmission mechanisms (odds ratio[OR] 1.91; 95% confidence interval[CI] 1.52-2.40), preventive methods (OR 1.83; 95% CI 1.46-2.30), and water treatment modalities (OR 2.75; 95% CI 2.16-3.50). Relative to pre-vaccination, participants were more likely post-OCV to report always treating water (OR 1.62; 95% CI 1.28-2.05). Respondents were also more likely to report hand washing with soap and water >4 times daily post-vaccine (OR 1.30; 95% CI 1.03-1.64). Knowledge of treating water as a cholera prevention measure was associated with practice of always treating water (OR 1.47; 95% CI 1.14-1.89). Post-vaccination, knowledge was associated with frequent hand washing (OR 2.47; 95% CI 1.35-4.51).

Conclusion
An OCV campaign in rural Haiti was associated with significant improvement in cholera knowledge and practices related to waterborne disease. OCV can be part of comprehensive cholera control and reinforce, not detract from, other control efforts in Haiti.

Justice in Global Pandemic Influenza Preparedness: An Analysis Based on the Values of Contribution, Ownership and Reciprocity [Indonesia]

Public Health Ethics
Volume 6 Issue 3 November 2013
http://phe.oxfordjournals.org/content/current

Justice in Global Pandemic Influenza Preparedness: An Analysis Based on the Values of Contribution, Ownership and Reciprocity
Meena Krishnamurthy, Matthew Herder
http://phe.oxfordjournals.org/content/6/3/272.abstract

Abstract
In December 2006, Indonesia decided to stop sending influenza virus specimens to the World Health Organization’s Global Influenza Surveillance Network (GISN). Indonesia justified its actions by claiming that they were in protest of the injustice of GISN. Its actions stimulated negotiations to improve the workings of GISN by developing and implementing a more just framework for ‘sharing influenza viruses and other benefits’. These negotiations eventually led to the adoption of a new framework for virus and benefit sharing in May 2011, at the World Health Assembly meeting. In this article, we critically evaluate Indonesia’s claims about the unjustness of GISN. We show that arguments based on the values of ownership, contribution and reciprocity work together to support Indonesia’s claim that it was owed an equal share in the benefits of GISN and, in turn, that GISN was unjust because of its failure to ensure this. We also use these values to evaluate the newly agreed upon framework for virus and benefit sharing. We suggest the new framework fails to give proper consideration to the values of ownership, contribution and reciprocity and, as a result, that it is fundamentally unjust.

From Google Scholar+ [to 23 November 2013]

From Google Scholar & other sources: Selected Journal Articles, Newsletters, Dissertations, Theses, Commentary

Evaluation of the immune response to human papillomavirus types 16, 18, 31, 45 and 58 in a group of Colombian women vaccinated with the quadrivalent vaccine
A Cómbita, D Duarte, J Rodríguez, M Molano… – Revista Colombiana de …, 2013
Objective To analyze whether the immune response to HPV-16,-18,-31,-45 and-58 capsids in women vaccinated with the quadrivalent vaccine induces cross-reactivity against other HPV virus-like particles (VLPs). Methods A total of 88 women aged between 18 and 27 …

[PDF] Humoral and cellular responses to a non-adjuvanted monovalent H1N1 pandemic influenza vaccine in hospital employees
MT Herrera, Y Gonzalez, E Juárez… – BMC Infectious Diseases, 2013
Background The efficacy of the H1N1 influenza vaccine relies on the induction of both humoral and cellular responses. This study evaluated the humoral and cellular responses to a monovalent non-adjuvanted pandemic influenza A/H1N1 vaccine in occupationally …

BASHH and the media [British Association for Sexual Health and HIV]
P Greenhouse, N Balmer, R Patel – Sexually Transmitted Infections, 2013
… This is probably best demonstrated by the media activity undertaken by BASHH around the human papillomavirus (HPV) vaccine, which is described in more detail below. Primarily, public education is a core function of the group. …

Special Focus Newsletters
RotaFlash – Rotavirus Vaccine Update   PATH 21 November 2013
Headline: Unanticipated benefits of rotavirus vaccination in the United States
http://vad.createsend4.com/t/ViewEmail/r/F18B988AE89914842540EF23F30FEDED/E38B11B8894CC5F5DBC23BD704D2542D

New York Times Editorial: Responding to a Meningitis Outbreak (Princeton University)

New York Times
http://www.nytimes.com/
Accessed 23 November 2013

Editorial
Responding to a Meningitis Outbreak
By THE EDITORIAL BOARD
Published: November 22, 2013

A vaccine approved for use in Europe and Australia but not in the United States will be imported to help quell an outbreak of bacterial meningitis at Princeton University. This is a good example of how two federal agencies — the Centers for Disease Control and Prevention and the Food and Drug Administration — can collaborate to reach a common-sense solution to protect the public’s health.

The university has been experiencing a small and slow-moving outbreak of a type of bacterial meningitis known as strain B. Four students and a visitor to the campus developed symptoms between March 22 and June 29; all have recovered. Two other students developed symptoms in October and early November. One has recovered; the other is recovering. On Friday, another student was diagnosed with meningitis, and tests are underway to determine whether it was caused by strain B.

Last year, some 160 cases of strain B were reported in the United States. The disease can cause headaches, high fevers and stiff necks, and it is fatal in 10 percent to 15 percent of the cases.

The vaccine currently used to prevent bacterial meningitis in this country protects against several other strains but not against strain B. The only vaccine proved to be effective against strain B is Bexsero, made by Novartis, which is based in Switzerland and which won regulatory approval for the vaccine in Europe in January and in Australia in August. The company has not pushed for approval here because it is concentrating on a vaccine against the other strains.

In this case, the C.D.C. requested permission to import the vaccine, and the F.D.A. approved it through a limited special process used occasionally to handle emergency situations, such as a shortage of critically needed cancer drugs last year. The vaccine will be available to all Princeton undergraduates starting next month, as well as to graduate students who live in dormitories and to people affiliated with the university who have specific medical conditions that put them at risk.

Although the imported vaccine has been approved only for use at Princeton, the C.D.C. should apply to have Bexsero available if a similar outbreak occurs somewhere else, and the F.D.A. should grant such approval.

Vaccines and Global Health: The Week in Review 16 Nov 2013

Vaccines and Global Health: The Week in Review is a weekly digest — summarizing news, events, announcements, peer-reviewed articles and research in the global vaccine ethics and policy space. Content is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage. You are viewing the blog version of our weekly digest, typically comprised of between 30 and 40 posts below all dated “29 June 2013″
.
Email Summary: Vaccines and Global health : The Week in Review is published as a single email summary, scheduled for release each Saturday eveningbefore midnight (EDT in the U.S.). If you would like to receive the email version, please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.
.
pdf version: A pdf of the current issues is available here: Vaccines and Global Health_The Week in Review_16 Nov 2013
.
Twitter: Readers can also follow developments on twitter: @vaxethicspolicy.
.
Links: We endeavor to test each link as we incorporate it into any post, but recognize that some links may become “stale” as publications and websites reorganize content over time. We apologize in advance for any links that may not be operative. We believe the contextual information in a given post should allow retrieval, but please contact us as above for assistance if necessary.
.
Support: If you would like to join the growing list of individuals who support this service and its contribution to their roles in public health, clinical practice, government, IGOs/NGOs, research, industry and academia, please visit this page at The Wistar Institute, our co-founder and fiduciary. Thank you…
.
David R. Curry, MS
Executive Director
Center for Vaccine Ethics and Policy
a program of the
– Division of Medical Ethics, NYU Medical School
– The Wistar Institute Vaccine Center
– Children’s Hospital of Philadelphia Vaccine Education Center
Associate Faculty, Division of Medical Ethics, NYU Medical School